University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
Dissertations & Theses in Veterinary and
Biomedical Science

Veterinary and Biomedical Sciences, Department of

Fall 9-2017

Cross-reactive Immunity to Porcine Reproductive
and Respiratory Syndrome Virus and its
Contribution to Protection
Ignacio Correas
University of Nebraska - Lincoln, icorreas@huskers.unl.edu

Follow this and additional works at: http://digitalcommons.unl.edu/vetscidiss
Part of the Animal Sciences Commons, Veterinary Infectious Diseases Commons, and the
Veterinary Microbiology and Immunobiology Commons
Correas, Ignacio, "Cross-reactive Immunity to Porcine Reproductive and Respiratory Syndrome Virus and its Contribution to
Protection" (2017). Dissertations & Theses in Veterinary and Biomedical Science. 23.
http://digitalcommons.unl.edu/vetscidiss/23

This Article is brought to you for free and open access by the Veterinary and Biomedical Sciences, Department of at DigitalCommons@University of
Nebraska - Lincoln. It has been accepted for inclusion in Dissertations & Theses in Veterinary and Biomedical Science by an authorized administrator
of DigitalCommons@University of Nebraska - Lincoln.

CROSS-REACTIVE IMMUNITY TO PORCINE REPRODUCTIVE AND
RESPIRATORY SYNDROME VIRUS AND ITS CONTRIBUTION TO PROTECTION

by

Ignacio Correas

A DISSERTATION

Presented to the Faculty of
The Graduate College at the University of Nebraska
In Partial Fulfillment of Requirements
For the Degree of Doctor of Philosophy

Major: Integrative Biomedical Sciences

Under the Supervision of Professor Fernando A. Osorio

Lincoln, Nebraska

September, 2017

CROSS-REACTIVE IMMUNITY TO PORCINE REPRODUCTIVE AND
RESPIRATORY SYNDROME VIRUS AND ITS CONTRIBUTION TO PROTECTION

Ignacio Correas, Ph.D.
University of Nebraska, 2017

Advisor: Fernando A. Osorio

Due to the vast geographical distribution and significant economic losses
generated, porcine reproductive and respiratory syndrome virus (PRRSV) can be
considered the most important swine pathogen of contemporary times. Current control and
eradication strategies against PRRSV have difficulty succeeding because of their complex
nature and the absence of an effective vaccine. A major obstacle for PRRSV vaccine
development is the broad heterogeneity of the virus, both at the genetic and antigenic level,
its rapid evolution, and an incomplete knowledge of the immune responses responsible for
clearing the virus from the host. Specifically, how known correlates of protection against
PRRSV—neutralizing antibodies and T cells—cross-react with heterologous isolates and
mediate cross-protection is inadequately understood. The objectives of this dissertation
were (i) to determine the extent of cross-reactivity of immune responses against PRRSV,
and (ii) to ascertain how cross-reactive immune responses mediate protection against
heterologous isolates. T cell responses were found to be cross-reactive among PRRSV-2
isolates, but extremely variable among individual animals, while the neutralizing antibody
response induced by a single infection with PRRSV was deemed to be solely self-

neutralizing. Sequential exposure to heterologous PRRSV-2 isolates elicited neutralizing
antibodies to the isolates used for infection and challenge, as well as other heterologous
PRRSV-2 isolates. Furthermore, prior exposure to PRRSV afforded cross-protection
against heterologous challenge, with reduction in viremia, tissue viral load and the extent
of microscopic lung lesions; however, protection was still suboptimal. T cell crossreactivity between PRRSV-1 and PRRSV-2 was evaluated at the structural protein level
and was deemed to be feeble or absent. Prior exposure to PRRSV-1 did not prime the T
cell response against the PRRSV-2 structural proteins after PRRSV-2 challenge.
Collectively, the results in this dissertation contribute to furthering the understanding of
immune responses against PRRSV and may be used in the development of a better vaccine.
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GENERAL INTRODUCTION

Since its emergence approximately three decades ago, PRRSV has made its way to
almost all large swine producing economies in the world. As the cost associated with the
disease continue to rise, significant progress in vaccine research and development is yet to
come. A major hurdle for developing a better vaccine against PRRSV is the high genetic
and antigenic variability of the virus, which, coupled with its rapidly evolving nature,
manifests as multiple isolates circulating and emerging within a region, farm, or animal.
Furthermore, how the known correlates of protection against PRRSV, T cells and
neutralizing antibodies, may cross-react and mediate protection against heterologous
isolates is incompletely understood. The principal objectives of this dissertation were (i) to
determine the extent of cross-reactivity of immune responses against PRRSV, and (ii) to
ascertain how cross-reactive immune responses mediate protection against heterologous
isolates. Overall, the purpose was to contribute to the understanding of immune responses
against PRRSV that could be used to improve the development of vaccines. This
dissertation consists of five chapters. Chapter I reviews the literature on PRRSV centering
on the virus, its biology and diversity, the disease it causes, how the immune system
combats it, and the current strategies for control and prevention, including the latest
advances in vaccine development. Chapter II describes the materials and methods utilized
throughout this dissertation. Chapter III reports on the evolution of T cell responses after
PRRSV infection, the cross-reactivity of immune responses observed in infected animals,
the relation of genetic divergence and cross-reactivity, and how cellular and humoral
immune responses against PRRSV associate. Chapter IV describes the cell- and antibody-
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mediated immune responses against PRRSV in previously infected or naïve animals,
before and after challenge, and the quality of protection achieved by prior PRRSV
exposure. Finally, Chapter V explores the cross-reactivity between the newly re-classified
PRRSV species, PRRSV-1 and PRRSV-2, at the structural protein level.
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CHAPTER I
LITERATURE REVIEW

1. Overview of porcine reproductive and respiratory syndrome
The late 1980’s saw the emergence of a new swine disease in the United States
characterized by severe reproductive losses, respiratory disease, reduction in growth, and
increased mortality (Keffaber, 1989). Similar outbreaks began to be reported in Europe
shortly after, and in 1991 the causative agent—a previously unidentified enveloped RNA
virus—was identified in the Netherlands and named Lelystad virus (Terpstra et al., 1991;
Wensvoort et al., 1991). The virus was first isolated and characterized in the United States
later that year and called VR-2332 (Benfield et al., 1992; Collins et al., 1992). The disease,
initially named “mystery swine disease”, “swine infertility and respiratory syndrome” and
“porcine epidemic abortion and respiratory syndrome” was finally designated porcine
reproductive and respiratory syndrome or PRRS, and its etiological agent porcine
reproductive and respiratory syndrome virus or PRRSV.
PRRSV infects pigs of all ages. An array of clinical signs can be observed in
PRRSV-infected pigs, which are most severe in sows and young pigs, and the disease is
characterized by persistent transmissible infections (Zimmerman et al., 2012). Although it
was first described in 1987, retrospective studies of swine sera found PRRSV-seropositive
animals as early as 1979 in Canada and 1986 in the United States (Carman et al., 1995;
Yoon et al., 1992). The first estimates of PRRSV herd seroprevalence in the United States
placed it at 33% in 1990 (Bautista et al., 1993b), while the latest available data, from 2006,
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showed that 71.1% of unvaccinated herds and 49.8% of unvaccinated animals were
PRRSV seropositive (USDA, 2009).
An assessment conducted in 2005 revealed that swine producers in United States
were estimated to lose $560 million each year due to PRRSV-associated declines in
reproductive health, increase in deaths, and reductions in the rate and efficiency of growth
(Neumann et al., 2005). Although improvements were made in dealing with the disease in
growing pigs, by 2013 the economic impact of PRRS had climbed to $664 million in annual
losses, mainly due to increased costs in the breeding herd (Holtkamp et al., 2013). In
perspective, these assessments almost double the estimated pre-eradication annual burden
attributable to classical swine fever virus, at $364 million, and pseudorabies virus (PRV),
at $36 million, when adjusted to 2004 dollars (Neumann et al., 2005).

2. Porcine reproductive and respiratory syndrome virus
2.1. Taxonomy
Until recently, PRRSV was considered one of four species within the genus
Arterivirus, family Arteriviridae, order Nidovirales. Other species in the genus included
Equine arteritis virus (EAV), the prototype species, Lactate dehydrogenase-elevating virus
(LaDV), and Simian hemorrhagic fever virus (SHFV) (Cavanagh, 1997; Faaberg et al.,
2012). A significant reorganization and expansion of the family Arteriviridae was recently
accepted in order to update the nomenclature and include newly discovered arteriviruses.
Newly established pairwise sequence comparison of complete coding genome regions and
open reading frame (ORF) 1b phylogeny were used to determine taxon-specific sequence
cut-offs (Kuhn et al., 2016). As a result, the family Arteriviridae now includes five genera,
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Equartevirus, Porartevirus, Simartevirus, Nesatervirus, and Dipatervirus. EAV, Wobbly
possum disease virus, and African pouched rat virus 1 are the sole members of the genera
Equartevirus, Dipartevirus, and Nesartevirus, respectively, while SHFV and other nonprimate arteriviruses belong to the genera Simartevirus. The species Porcine reproductive
and respiratory syndrome virus was split to accommodate the divergence between the
European or type 1 and North American or type 2 genotypes, which are now considered
separate species, PRRSV-1 and PRRSV-2, respectively, within the genus Porartevirus,
which also includes LaDV and Rat arterivirus 1 (Adams et al., 2016; Adams et al., 2017).

2.2. Genome organization and replication
The PRRSV genome consists of a 14.9–15.5 kilobase (kb) single positive strand of
RNA that is 3’-polyadenylated and encodes multiple non-structural and structural proteins.
The virus employs a complex array of replication and expression mechanisms which
include the rearrangement of host membranes to establish viral replication and transcription
complexes (RTC), synthesis and expression of genomic RNA, and synthesis and
expression of subgenomic (sg) messenger RNA (mRNA).

2.2.1. Genome organization
The PRRSV genome (Figure 1.1) encodes 11 ORFs flanked by 5’ and 3’
untranslated regions (UTR). The large overlapping replicase ORF1a/b occupies the 5’proximal three-quarters of the genome, which gives rise to four distinct polyprotein (pp)
products that are co-translationally and post-translationally processed into 16 distinct nonstructural proteins (nsps) by virally-encoded proteinases (Kappes and Faaberg, 2015).
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The autocatalytic processing of pp1a, encoded by ORF1a, yields ten nsps: nsp1α,
nsp1β, nsp2, nsp3, nsp4, nsp5, nsp6, nsp7α, nsp7β, and nsp8 (Li et al., 2012). ORF1b
translation requires a programmed -1 ribosomal frameshift (PRF) that allows for the 3’
extension of ORF1a into ORF1b to generate pp1ab, which in turn yields the ten nsps
encoded in pp1a plus nsp 9 through 12 (Snijder et al., 2013). Of the four virally encoded
proteases described for PRRSV, three are papain-like cysteine proteinases (PLPs) residing
in nsp1α (PLP1a), nsp1β (PLP1b), and nsp2 (PLP2), and one is a serine proteinase (SP) in
nsp4. PLP1a cleaves the nsp1α-nsp1β junction and PLP1b cleaves the nsp1β-nsp2 junction,
whereas PLP2 is responsible for cleaving nsp2 from nsp3 and the main SP processes all
remaining nsp products (Li et al., 2015).
A recently described PRF site located within the nsp2 coding region is responsible
for generating ORF1a’, which yields two additional nonstructural protein products: a -2
PRF produces an nsp2-related transframe protein designated nsp2-TF, and a -1 PRF yields
a truncated nsp2 variant named nsp2-N (Fang et al., 2012; Li et al., 2014). A highly
conserved putative RNA-binding motif located within the PLP1b domain of nsp1β is
responsible for the transactivation of this PRF, which otherwise lacks any obvious
stimulatory RNA secondary structure (Li et al., 2014).
The PRRSV structural proteins are encoded by eight overlapping ORFs contained
within a set of six sg mRNAs that are generated via negative-strand intermediates from the
3’ portion of the genome. Regardless of their polycistronic nature, most sg mRNA are
functionally monocistronic (Meng, 2000; Meng et al., 1996).
Flanking the protein coding regions, the 5’UTR and 3’UTR of arteriviruses hold
conserved RNA structures considered essential components for viral replication and
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protein translation. The 5’UTR is likely to contain a cap structure, and contains the leader
transcription regulatory sequence (TRS) hairpin that is essential for sg mRNA synthesis
(Sagripanti et al., 1986; van den Born et al., 2004).

2.2.2. Viral replication sites
A hallmark of all positive-stranded RNA virus replication is the formation of
organelle-like structures to replicate their genome using host membrane modifications
(Romero-Brey and Bartenschlager, 2014). It has been proposed that the association of viral
RNA synthesis with dedicated membranes affords viruses three advantages: it confines
viral RNA synthesis to compartments where viral proteins and precursors can be optimally
concentrated, it spatially distributes and coordinates the various processes of the infectious
cycle, and it shields double stranded RNA species preventing or delaying their recognition
by the host’s innate immune responses (van der Hoeven et al., 2016). For EAV, the
formation of these dedicated membranes—called double membrane vesicles (DMVs)—
was shown to require the presence of both nsp2 and nsp3 (Snijder et al., 2001).

2.2.3. Genome replication
Upon entry into the cell, the PRRSV genome acts as template for the synthesis of
the replicase polyproteins encoded in ORF1a/b, which is presumably initiated by ribosomal
scanning (van den Born et al., 2005). ORF1b encodes the nsps responsible for PRRSV
genome replication: nsp9, the RNA-dependent RNA polymerase (RdRp), nsp10, the RNA
helicase, and nsp11, the nidovirus uridylate-specific endoribonuclease (NendoU) (Snijder
et al., 2013).
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The RdRp, the catalytic subunit within the RTC, is able to initiate de novo RNA
synthesis in the absence of other viral or cellular proteins in a template-specific and primerindependent manner; however, it was postulated that the RdRp might require additional
viral or cellular co-factors to perform effectively (Beerens et al., 2007). Unlike other
members of the order Nidovirales, the arterivirus RdRp lacks 3’ proofreading capacity,
which contributes to a high rate of random mutations (Kappes and Faaberg, 2015). The
RdRp is responsible for synthesizing a genome-length minus strand, or anti-genome, that
will subsequently serve as template for the generation of new viral genomes.

2.2.4. Synthesis of subgenomic messenger RNAs
PRRSV structural proteins are encoded by a set of six 3’-co-terminal nested sg
mRNAs (Meng et al., 1996). The viral RdRp is responsible for synthesizing sg mRNAs
that contain the 5’UTR and the polyadenylated 3’UTR and one or more ORFs from the 3’
region of the genome, but lack the large replicase ORF1a/b (den Boon et al., 1996).
Arteriviruses use a form of discontinuous RNA transcription, a mechanism resembling
copy-choice RNA recombination, where through base pairing of short conserved TRSs the
5’UTR (leader TRS) fuses to one of many downstream 3’ sites (body TRS). The process
first requires the generation of negative strand sg RNAs which will be subsequently used
to synthesize sg mRNAs (Pasternak et al., 2001; van Marle et al., 1999). The abundance of
sg mRNAs can be correlated with the stability of the duplex between leader and body TRS
sites (Pasternak et al., 2004).
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2.3. Viral structure and assembly
The PRRSV virion is enveloped, pleomorphic, roughly spherical or oval with an
average diameter of 58 nm (Spilman et al., 2009). The PRRSV genome is encapsidated by
the N protein and the viral envelope contains two major proteins— glycoprotein (GP) 5
and M—and five minor proteins, GP2, GP3, GP4, E, and the recently discovered ORF5a
protein (Dokland, 2010; Johnson et al., 2011). The viral particles are smooth, probably due
to the small ectodomains of the major envelope proteins; yet, a few 10-15 nm protrusions
can be observed, likely corresponding to the less abundant minor glycoproteins (Spilman
et al., 2009). The buoyant density of the particle is 1.19 in cesium chloride, 1.14 in sucrose,
and 1.19 g/cm in a glycerol-tartrate gradient (Wensvoort et al., 1992).

2.3.1. Nucleocapsid
The nucleocapsid core of the PRRSV particle is separated from the envelope by a
3 nm gap and consists of a 10-11 nm thick two-layered shell that surrounds a hollow central
cavity averaging 13-14 nm in diameter (Spilman et al., 2009). Although the conformation
of the nucleocapsid is yet unknown, it has been suggested that it may adopt a helical or
loosely organized filamentous structure, resembling that of coronaviruses (Dokland, 2010).
The 15-kDa N protein, encoded by ORF7, is highly basic, interacts with the viral
RNA to form the viral nucleocapsid, and constitutes about 20-40% of the protein content
of the virion (Bautista et al., 1996). The N protein is phosphorylated and is incorporated
into virions a disulfide-linked homodimer, and both protein oligomerization and direct
RNA binding motifs have been implicated in RNA binding (Wootton et al., 2002; Wootton
and Yoo, 2003). Although the PRRSV life cycle occurs in the cytoplasm, the N protein has
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been found to localize in the nucleus and nucleolus of infected cells (Rowland et al.,
1999a).

2.3.2. Major envelope proteins
The non-N-glycosylated 16-kDa M protein, encoded by ORF6, and the Nglycosylated 25-kDa GP5, encoded by ORF5, form a disulfide-linked heterodimer on the
PRRSV envelope that is deemed crucial for viral particle assembly and budding (Mardassi
et al., 1996; Wissink et al., 2005). GP5 is the most variable structural protein of PRRSV,
sharing only ~50% amino acid homology between PRRSV-1 and PRRSV-2. Strains and
isolates within each species share ~88% and 89-94% GP5 amino acid identity, respectively
for PRRSV-1 and PRRSV-2 (Andreyev et al., 1997; Meng et al., 1995b; Suarez et al.,
1996). The number of N-glycosylation sites of GP5 is variable. Ansari et al. (2006) showed
that of the predicted N-glycosylation sites of GP5—located on sites 34, 44, and 51—the
one mapped to reside 44 was essential for viral infectivity; however, Wei et al. (2012a)
later demonstrated that mutation of individual N-glycosylation sites in GP5—mapped to
residues 30, 34, 44, and 51—did not have such an effect.

2.3.3. Minor glycoprotein heterotrimer
The PRRSV minor envelope glycoproteins GP2 (29–30-kDa), GP3 (45–50-kDa),
and GP4 (31–35-kDa) are encoded by ORF2a, ORF3, and ORF4, and contain two, seven,
and four potential N-glycosylation sites, respectively (Meulenberg and Petersen-den
Besten, 1996; van Nieuwstadt et al., 1996). Although they are considered essential for viral
infectivity, they were found not to be essential for viral particle assembly (Wissink et al.,

11
2005). All three minor glycoproteins are incorporated into the virion in smaller proportions
than the major envelope proteins and the N protein (de Lima et al., 2009; van Nieuwstadt
et al., 1996).
Wissink et al. (2005) first reported that GP2, GP3, GP4, and the E protein were
assembled into virions as a multimeric complex that jointly migrated through the Golgi
complex and, unless expressed together, were retained in the endoplasmic reticulum (ER).
It was later demonstrated that all three minor glycoproteins interact with each other, GP2
and GP4 interact with the major envelope glycoprotein GP5, and GP4 plays a central role
in the generation of the heterotrimer and its interaction with GP5 (Das et al., 2010).
Das et al. (2011) established that to produce infectious PRRSV particles Nglycosylation at position 184 of GP2, positions 42, 50, and 131 of GP3, and any three of
the four sites of GP4 were essential; however, Wei et al. (2012b) later demonstrated that
the lack of N-glycosylation at the aforementioned positions had no effect on virus recovery,
and that the absence of one or two N-glycosylation sites on GP4 were not lethal, but the
absence of three was. Moreover, it was demonstrated that both N-glycosylation sites on
GP2 were deemed dispensable for particle assembly and infectivity of PRRSV-1 (Wissink
et al., 2004).

2.3.4. Small envelope (E) and ORF5a proteins
Encoded by ORF2b, the 10-kDa E protein is dispensable for PRRSV virion
assembly but essential for viral infectivity, and has been implicated in promoting the
uncoating of the virion and release of the viral genome into the cytoplasm (Lee and Yoo,
2006; Wu et al., 2001). The ORF5a transmembrane protein (5–6 kDa) is encoded by the
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same RNA sequence that encodes the hypervariable glycosylation-rich ectodomain region
of GP5, and has been found to be essential for virus viability and to interact with GP4 and
the E protein (Johnson et al., 2011; Robinson et al., 2013; Sun et al., 2013; Sun et al., 2015).

2.3.5. Assembly and release
Little is known about the morphogenesis and assembly of PRRSV particles. The
arterivirus-induced DMVs and the ER form a reticulovesicular network which intertwines
with tubules abundant in N protein, and it has been hypothesized that morphogenesis and
assembly are coordinated in said space and that genome encapsidation is initiated at the
site of RNA synthesis (Knoops et al., 2012; Tijms et al., 2002). PRRSV nucleocapsids were
shown to bud from the smooth ER and accumulate in the lumen of the ER or Golgi vesicles,
and it has been suggested that the N protein self-associative properties likely provide the
basis for nucleocapsid assembly (Dea et al., 1995; Pol et al., 1997; Wootton and Yoo,
2003). Wieringa et al. (2004) proposed that the newly synthesized nucleocapsids are likely
to bind to exposed domains of the envelope proteins in the process of viral budding, and
Dea et al. (1995) showed that the viral particles accumulated in the infected cells are
released by exocytosis.

2.3. Virus-host interactions
2.3.1. Tropism, receptors, and entry
PRRSV has a very limited tropism of cells and hosts, primarily replicating in
porcine alveolar macrophages (PAM) and macrophages of lymphoid tissues of pigs (Duan
et al., 1997b; Mardassi et al., 1994; Teifke et al., 2001). Macrophage precursor cells, such
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as bone marrow cells, peripheral blood monocytes, and peritoneal macrophages are largely
refractory to PRRSV infection (Duan et al., 1997a, b). Loving et al. (2007) demonstrated
that monocyte-derived dendritic cells (DCs)—that may still retain specific characteristics
of monocytes/macrophages—are permissive to PRRSV infection, but primary lung DCs
are not. The MA-104 African green monkey kidney cell line, and its derivatives MARC145 and CL 2621 cells, can support PRRSV replication and are widely used in research
(Bautista et al., 1993a; Benfield et al., 1992; Kim et al., 1993).
Heparan sulfate, vimentin, CD151, CD163, sialoadhesin (SIGLEC1 or CD169),
and DC-SIGN have all been implicated as potential cellular receptors for PRRSV (Van
Breedam et al., 2010).
CD163 was identified by direct functional screening of a complementary DNA
(cDNA) expression library derived from PAM, and it conferred PRRSV-permissiveness to
otherwise non-permissive cell lines (Calvert et al., 2007). GP2 and GP4 have been shown
to mediate the interaction with certain domains of CD163, and their N-glycosylation status
was shown to be of cardinal importance (Das et al., 2010; Das et al., 2011; Van Gorp et al.,
2010; Wei et al., 2012b). Tian et al. (2012) demonstrated that a chimeric PRRSV encoding
the GP2-4 and E protein of EAV acquired the broad tropism typical of EAV, and
Whitworth et al. (2016) showed that CD163-knockout pigs were completely refractory to
PRRSV infection. Thus, it is widely accepted that CD163 is the major cellular receptor for
PRRSV, and its interaction with the minor envelope glycoproteins is responsible for viral
tropism. Nonetheless, the sole presence of CD163 in many cell lines does not grant
permissiveness to PRRSV infection, and it has been suggested that other molecules,
including sialoadhesin, could be also involved in this process (Welch and Calvert, 2010).
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Recently, it was reported that PRRSV-1 and PRRSV-2 interact with different motifs of
CD163 (Wells et al., 2017). Virions enter the cell through receptor-mediated, clathrindependent endocytosis, followed by fusion of endocytic vesicles with endosomes, where
low pH is required for virus uncoating (Kreutz and Ackermann, 1996; Nauwynck et al.,
1999).

2.3.2. Viral modulation of innate immune responses
Type I interferons (IFNs) IFN-α and IFN-β—a critical component of the innate
immune response—are potent antiviral cytokines that induce cellular antiviral proteins,
enhance antigen presentation, and promote adaptive immune responses (McNab et al.,
2015). IFN-α response during PRRSV infection can be characterized as meager or null,
which suggests that the virus may actively suppress type I IFN production. Six proteins of
PRRSV have been implicated in type I IFN antagonism: nsp1α, nsp1β, nsp2, nsp4, nsp11,
and N (Albina et al., 1998a; Beura et al., 2010; Sagong and Lee, 2011).
Type I IFN suppression has been extensively demonstrated for nsp1 and its two
subunits (nsp1α and nsp1β). Beura et al. (2010) were the first to report that five PRRSV
nsps (nsp1α, nsp1β, nsp2, nsp4, and nsp11) had strong to moderate inhibitory effect on the
activation of the IFN-β promoter. Blocking of the type I IFNs response by nsp1α has been
shown to occur through CREB-binding protein degradation, inhibition of nuclear factor
(NF)-kB signaling, and inhibition of the tumor necrosis factor (TNF)-α promoter (Han and
Yoo, 2014; Ke and Yoo, 2017). The mechanisms by which nsp1β suppresses type I IFNs
include inhibition of IFN regulatory factor (IRF) 3 phosphorylation, NF-κB nuclear
translocation, STAT1 phosphorylation and nuclear translocation, IFN-stimulated gene
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(ISG) factor 3 nuclear translocation, and suppression of the TNF-α promoter, among others
(Han and Yoo, 2014; Sun et al., 2012). It was recently demonstrated that nsp1α triggers the
degradation of the swine leukocyte antigen (SLA) class I in a ubiquitin proteasome
dependent fashion, further interfering with the host’s immune responses (Du et al., 2015).
The PLP2 domain of nsp2 antagonizes type I IFN induction by interfering with the
NF-κB signaling pathway and inhibiting the phosphorylation and nuclear translocation of
IRF3 and the antiviral function of ISG15 (Wang and Zhang, 2014). The SP domain of nsp4
antagonizes NF-κB, while the NendoU domain of nsp11 blocks the phosphorylation and
nuclear translocation of IRF3, inhibits NF-κB signaling, and suppresses the expression of
the cytoplasmic antiviral receptors MAVS and RIG-I (Ke and Yoo, 2017; Sun et al., 2012)
While the N protein was found to suppress type I IFN production by inhibiting IRF3
phosphorylation and nuclear translocation, it was also found to activate NF-κB (Sagong
and Lee, 2011; Sun et al., 2012).
PRRSV infection reduces or suppresses IFN-α and pro-inflammatory cytokine
production in plasmacytoid dendritic cells (pDCs)—a DC subset capable of producing
large amounts of IFN-α—by downregulating the expression of interferon regulatory genes,
and was shown to repress natural killer (NK) cell cytotoxicity independent of NK cell
frequency (Calzada-Nova et al., 2011; Dwivedi et al., 2012). Because cell-mediated
immunity relies on IFN-α and pDCs for maturation, the meager IFN-α response to PRRSV
is expected to negatively impact the host’s adaptive immune responses (Loving et al.,
2015).

16
2.3.3. Mechanisms of cell injury
Four mechanisms of cell injury have been studied for PRRSV: apoptosis of infected
macrophages

and

surrounding

cells,

production

of

pro-inflammatory

and

immunomodulatory cytokines, polyclonal B cell activation, and reduced phagocytosis and
killing of bacteria by macrophages.
In PRRSV-infected animals’ apoptosis was shown to occur in both lung and
lymphoid tissue; however, it was observed mostly in PRRSV-uninfected cells, suggesting
that PRRSV-mediated apoptosis affects bystander cells through an indirect mechanism
(Sirinarumitr et al., 1998; Sur et al., 1998). PRRSV-induced apoptosis was shown to be
dependent on the activation of caspase-8 and caspase-9—signaling through both the
extrinsic and intrinsic pathway—and multiple and complex pathways have been implicated
in this process (Lee and Kleiboeker, 2007).
The synthesis and presence of the pro-inflammatory cytokines interleukin (IL)-1
and IL-6, that cause pyrexia, inflammation, and promote the infiltration and activation of
leukocytes, was found to be upregulated in the lungs of PRRSV-infected pigs (Liu et al.,
2010; Van Reeth et al., 1999). The immunomodulatory cytokine IL-10—responsible for
inhibiting the production of pro-inflammatory cytokines—was also shown to be
upregulated in pigs infected with PRRSV (Suradhat and Thanawongnuwech, 2003).
Nonetheless, even though it is widely accepted that PRRSV suppresses IFN-α and TNF-α
production in infected animals, certain PRRSV isolates have been shown to enhance it (Liu
et al., 2010).
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2.4. Phenotype and genotype diversity
Due to a concurrent emergence and similar disease syndromes, until recently,
PRRSV-1 and PRRSV-2 were considered two genotypes of the same virus species.
However, PRRSV-1 and PRRSV-2 are antigenically distinct viruses that share common
antigenic epitopes with moderately conserved genomes (Murtaugh et al., 1995; Nelsen et
al., 1999; Nelson et al., 1993).
RNA polymerase infidelity is primarily responsible for the ever-increasing
diversity of PRRSV. PRRSV calculated nucleotide substitution rates are very high;
however, no biochemical data is available on the base incorporation specificity for the viral
replication complex (Murtaugh et al., 2010). PRRSV diversity can also be attributed to the
contribution of genomic recombination, which has been demonstrated computationally and
experimentally (Murtaugh et al., 2001; Murtaugh et al., 2002; van Vugt et al., 2001).
Only about 60% nucleotide similarity exists between PRRSV-1 and PRRSV-2
(Murtaugh et al., 2010). Nine lineages have been proposed and defined using ORF5
phylogeny for PRRSV-2, seven of which include predominantly North American isolates,
and two contain exclusively East Asian isolates (Shi et al., 2010b). For PRRSV-1, genetic
and biological studies support its subdivision into three subtypes considering ORF5 and
ORF7 genetic diversity (Stadejek et al., 2013).
Canada has been suggested as the potential origin of PRRSV-2, due to having the
earliest record of a positive serum sample (Carman et al., 1995; Shi et al., 2010a), while
Eastern Europe has been hypothesized to be the origin of PRRSV-1 (Stadejek et al., 2006).
Hanada et al. (2005) proposed that PRRSV-1 and PRRSV-2 diverged not long before
emergence, somewhere between the early 1970’s and mid 1980’s, which was followed by
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an extremely high substitution rate; nevertheless, this scenario was immediately questioned
due to inappropriate methodology and the use an uninformative data set (Forsberg, 2005).
Alternatively, and using an expanded ORF3 dataset, Forsberg (2005) proposed an early
divergence between PRRSV-1 and PRRSV-2, around the late 1800’s, followed by a long
independent evolution in the two continents.
Two hypothesis have been suggested for the origin of PRRSV. Plagemann (2003)
maintains that PRRSV had an LaDV-like ancestor circulating in rodents that was adapted
to Eurasian wild boars. Wild boars from Europe were introduced into the United States in
the early 1900’s, and it has been hypothesized that PRRSV evolved separately in the wild
boar population before its introduction into the domestic pig population; however, PRRSV
prevalence studies in wild boars argue against this theory (Plagemann, 2003; Reiner et al.,
2009). Alternatively, Murtaugh et al. (2010) suggest a single Eurasian origin of PRRSV,
followed by a translocation of infected swine to North America, after which the virus
evolved independently in both Eurasia and North America for an indeterminate period
giving rise to PRRSV-1 and PRRSV-2, respectively.

3. Epidemiology and pathogenesis
PRRSV is distributed worldwide, including the three largest swine producing
regions in the world: China, the European Union, and the United States. Because available
serology tests do not differentiate virus-exposed from vaccinated animals, PRRSV
seroprevalence is difficult to estimate; however, 71.1% of unvaccinated herds and 49.8%
of unvaccinated animals in the United States were PRRSV seropositive in 2006 (USDA,
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2009). Although PRRSV infects only domestic and feral pigs, seroprevalence studies show
a very low prevalence in wild boars (Saliki et al., 1998; Wyckoff et al., 2009).

3.1. Transmission, infection, and shedding
PRRSV infection can occur both directly and indirectly. PRRSV horizontal
transmission has been described for the intranasal, intramuscular, oral, and vaginal routes,
and the probability that a given dose will infect an animal differs by the route of exposure
and isolate (Benfield et al., 2000; Cutler et al., 2011; Hermann et al., 2005; Hermann et al.,
2009; Yoon et al., 1999). Husbandry practices, such as ear notching, tail docking, and teeth
clipping could lead to PRRSV exposure, and percutaneous (parenteral) exposure is the
route with the lowest minimum infectious dose (Pileri and Mateu, 2016). Otake et al.
(2002) demonstrated that transmission of PRRSV could be achieved through contaminated
needles and Bierk et al. (2001) suggested that biting and fighting between animals could
result in PRRSV exposure. PRRSV transplacental infection occurs in late-term gestation
and results in fetal death or birth of infected pigs that are weak or appear normal
(Karniychuk and Nauwynck, 2013).
Transmission of PRRSV between herds occurs through the introduction of animals,
semen, and—less likely—aerosol transmission (Goldberg et al., 2000; Mortensen et al.,
2002). Upon entering a naïve herd, an epidemic phase lasting 1–5 months ensues, where
all pigs get infected with PRRSV, after which infection becomes endemic, usually when a
majority of animals achieve a protective immunity (Pileri and Mateu, 2016). PRRSV tends
to circulate within a herd indefinitely. The continual availability of susceptible animals,
either through birth, purchase, or loss of protective immunity, sustains persistence PRRSV,
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and is more likely to occur as the herd size increases and when gilts are not properly
isolated from sows (Evans et al., 2010; Nodelijk et al., 2000).
PRRSV infection is chronic and persistent. Viremia can be detected up to a month
post infection (PI) or more, while viral replication can be detected up to 150 days post
infection (DPI) or more in lymphoid tissue (Allende et al., 2000; Horter et al., 2002; Wills
et al., 1997b). PRRSV persistence has been described in pigs exposed in utero, as a young
animal and as an adult, and seems to last for 3–4 months PI, after which it is cleared by the
host (Bierk et al., 2001; Christopher-Hennings et al., 1995; Rowland et al., 1999b; Wills et
al., 2003).
PRRSV-infected animals shed virus in saliva, nasal secretions, urine, semen, and
less frequently in milk and feces (Christianson et al., 1993; Rossow et al., 1994; Swenson
et al., 1994; Wagstrom et al., 2001; Wills et al., 1997a). Cho et al. (2006) reported that
shedding of virus from infected animals is dependent on the pathogenicity of the isolate.

3.2. Pathogenesis, clinical signs, and lesions
Immediately after exposure to PRRSV, viral replication occurs in local permissive
macrophages after which the virus spreads to lungs, lymphoid and other tissues. Viremia
can be detected as early as 12 hours PI—most pigs develop viremia by 24 hours PI—and
peaks at 7–14 DPI (Rossow et al., 1995). After peaking, viremia decreases rapidly, and
most pigs are not viremic by 28 DPI; however, persistent infection continues in tonsil
and/or lymph nodes for extended periods of time, where virus is produced by a low level
of continuous replication (Allende et al., 2000; Wills et al., 2003).
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Different clinical presentations of PRRSV infection can be observed depending on
the age of the pig, pregnancy status, and stage of gestation of the sow or gilt. Reproductive
failure occurs due to late-term exposure of pregnant sows or gilts, and litters are composed
of any combination of normal pigs, weak variably sized pigs, and dead pigs that are fresh
stillborn, autolytic, partially mummified, or completely mummified fetuses (Christianson
et al., 1992; Mengeling et al., 1998). Sows have delayed return to estrus, low conception
rate, and, infrequently, agalactia (Hopper et al., 1992). In suckling pigs—infected in utero
or at (or shortly after) birth—PRRS is characterized by severe dyspnea and tachypnea and
high pre-weaning mortality, while weaning and grower pigs experience anorexia, lethargy,
dyspnea (or hyperpnea), reduction in average daily gain, and an increase in mortality due
to concurrent bacterial infections (Hopper et al., 1992; Stevenson et al., 1993). PRRSVinfected boars may lack libido and have variable reduction in semen quality, in addition to
anorexia, lethargy, and respiratory clinical signs (Done et al., 1996; Prieto et al., 1996). In
breeding herds, endemic PRRS is sustained by subclinical infections, with occasional small
outbreaks of clinical PRRS in gilts and, less commonly, in sows (Dee and Joo, 1994;
Hopper et al., 1992).
Gross lung lesions associated with PRRSV vary from none to multifocal tanmottled consolidation, and are commonly complicated by lesions arising from associated
bacterial infections (Done and Paton, 1995; Halbur et al., 1995b). In young pigs, lymph
nodes are markedly enlarged and vary from solid to polycystic (Halbur et al., 1995a;
Rossow et al., 1994). Aborted fetuses due to PRRSV are late term and the body condition
ranges from fresh to autolyzed (Christianson et al., 1992; Lager and Mengeling, 1995).
Microscopically, lung lesions are characterized by septal thickening, alveoli lined by
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hypertrophied and hyperplastic type II pneumocytes, hypertrophy of peribronchial
lymphoid tissue, and lymphoplasmacytic perivascular cuffing (Halbur et al., 1993; Rossow
et al., 1995). Lymphoid tissue lesions include germinal center hypertrophy and hyperplasia,
germinal center necrosis, and multiple cystic spaces with polykaryocytes (Halbur et al.,
1995b; Rossow et al., 1994). Other microscopic findings include vasculitis varying in
severity, myocarditis, and encephalitis (Halbur et al., 1995b; Rossow et al., 1994). Rarely,
PRRSV-induced severe meningoencephalitis has been found to occur (Rossow et al.,
1999).

4. Adaptive immune responses
Although PRRSV infection is chronic and persistent, most pigs successfully clear
the virus 3–4 months PI (Allende et al., 2000). Protective immunity against PRRSV can be
achieved, and both antibody-mediated and cell-mediated immune responses have been
studied in the context of PRRSV infection; however, the details behind the significant
amount of time required for clearance and disease resolution are still elusive.

4.1. Antibody-mediated immune responses
Antibodies against PRRSV can be detected as early as 7–9 DPI, but early antibodies
have been proven to lack virus neutralizing activity both in vitro and in vivo (Lopez et al.,
2007; Yoon et al., 1994). PRRSV-neutralizing antibodies can be detected no earlier than
28 DPI, and up to 6 months PI or more; however, PRRSV still manages to persist in tissues
and continues to be shed in their presence (Allende et al., 2000; Bierk et al., 2001; Meier
et al., 2003; Nelson et al., 1994; Yoon et al., 1994).
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4.1.1. Non-neutralizing antibodies
PRRSV-specific immunoglobulin (Ig) M against GP5 and the M and N proteins is
first detected at 7 DPI, peaks at 14–21 DPI, and becomes undetectable by 35–42 DPI, while
PRRSV-specific IgG peaks at 21–28 DPI and remains high through the persistent phase of
infection (Loemba et al., 1996; Nelson et al., 1994). Long-lasting antibody responses
targeted towards nsp1, nsp4, nsp7, and—to a lesser extent—nsp8 have been described
(Brown et al., 2009).
Non-neutralizing antibodies against PRRSV have been linked to antibodydependent enhancement (ADE) of infectivity. In vitro, sub-neutralizing amounts of
PRRSV-specific IgG were able to increase PRRSV yields and infection rates; however,
significant differences were found between isolates (Gu et al., 2015; Yoon et al., 1997;
Yoon et al., 1996). In contrast, Delputte et al. (2004) were unable to demonstrate ADE for
PRRSV-1 in vitro. In vivo, passive transfer of non-neutralizing or sub-neutralizing IgG
followed by infection with PRRSV showed greater duration of viremia, increased rectal
temperatures, and interstitial pneumonia (Lopez et al., 2007; Yoon et al., 1996);
nonetheless, Lopez et al. (2007) argued that the increased rectal temperature and interstitial
pneumonia they observed could be attributed to pro-inflammatory cytokines co-salted out
with the IgG fractions.

4.1.2. Neutralizing antibodies
Albina et al. (1992) were the first to describe the presence of neutralizing antibodies
in PRRSV-infected animals. Passive transfer studies proved that homologous neutralizing
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antibodies could protect sows and weaned pigs from viremia and, in certain cases, afford
them sterilizing immunity (Lopez et al., 2007; Osorio et al., 2002). The breadth and
contribution to cross-protection of heterologous neutralizing antibody response against
PRRSV is unclear. Kim et al. (2007) showed that sera from pigs inoculated with diverse
PRRSV-2 isolates effectively neutralized homologous virus, but meager crossneutralization was observed. Choi et al. (2016) further demonstrated the absence of crossneutralizing antibodies between PRRSV-1- and PRRSV-2-infected animals. Using a panel
of 30 hyperimmune monospecific sera and 39 PRRSV-1 isolates it was established that
certain PRRSV-1 isolates were more prone to cross-neutralization than others (MartinezLobo et al., 2011). Recently, broadly cross-neutralizing antibodies have been described in
commercial sows after multiple PRRSV exposures (Robinson et al., 2015).
Targets of neutralizing antibodies have been mapped to GP3, GP4, GP5, and the M
protein (Cancel-Tirado et al., 2004; Costers et al., 2010; Delputte et al., 2004; Ostrowski
et al., 2002; Plagemann et al., 2002; Vanhee et al., 2011; Zhou et al., 2012). Several
mechanisms have been proposed for PRRSV evasion of neutralizing antibodies. The
absence of N-linked glycosylation in GP3 and GP5 was determined to enhance both the
sensitivity of PRRSV to neutralization and its ability to rapidly elicit robust neutralizing
antibodies in vivo (Ansari et al., 2006; Vu et al., 2011). A decoy epitope in GP5, described
by Ostrowski et al. (2002), was shown to induce a rapid non-neutralizing antibody response
in detriment of neutralizing antibodies targeting a nearby epitope.
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4.2. Cell-mediated immune responses
A transient reduction in CD4+ T cells, at 3–7 DPI, followed by a return to normal
levels by 7–14 DPI, can be observed in PRRSV-infected animals, while the number of
CD8+ T cells is increased in both blood and lung (Albina et al., 1998b; Nielsen and Botner,
1997; Samsom et al., 2000). Furthermore, γδ T cells are elevated in PRRSV-infected
animals from 14 DPI through 70 DPI and increases in both CD8+ and CD4+/CDα+ doublepositive (DP) T cells can be observed in lymphoid tissue (Gomez-Laguna et al., 2009; Olin
et al., 2005). Correspondingly, piglets infected in utero with PRRSV exhibit a reduced
number of CD4+ T cells at birth that lasts for two weeks, and a substantial increase in the
number of CD8+ T cells (Feng et al., 2002; Nielsen et al., 2003).
Bautista and Molitor (1997) showed that the PRRSV-specific T cell proliferation
response could be first detected at four weeks PI, peaked at seven weeks PI, and declined
after 11 weeks PI. Antigen-induced proliferation of γδ T cells showed similar kinetics (Olin
et al., 2005). Lymphoprolipheration studies showed that the PRRSV GP5, M, and N
proteins were the strongest inducers of cell-mediated immunity (Bautista et al., 1999).
The cell-mediated immunity to PRRSV, measured by the frequency of PRRSVspecific IFN-γ secreting cells (SC) in peripheral blood mononuclear cells (PBMC), is weak
and late to appear, but is prolonged and relatively stable once established (Meier et al.,
2003). PRRSV-specific IFN-γ SC are undetectable until three weeks PI, stay moderately
low for the subsequent ten weeks, followed by a gradual and steady surge (Meier et al.,
2003). Xiao et al. (2004) were able to detect antigen-specific IFN-γ SC as early as two
weeks PI, and observed that PRRSV-specific T cells in peripheral blood showed substantial
variation over time and among animals. They further proved the absence of any correlation

26
between PRRSV load and PRRSV-specific T cell frequencies in lung and lymphoid tissue
both at the acute and chronic stages of the disease (Xiao et al., 2004). Phenotypic analysis
performed by Meier et al. (2003) revealed that the majority of PRRSV-specific IFN-γ SC
were CD4+/CDα+ DP T cells, with a smaller proportion (~20%) of CD4-/CD8αβ+
cytotoxic T cells. Porcine CD4+/CD8+ DP T cells have been associated with immune
memory function and shown to have B cell helper function (Zuckermann, 1999). T cell
epitopes have been mapped to nsp2, nsp9, and nsp10, and the structural proteins GP4, GP5,
M, and N (Burgara-Estrella et al., 2013; Diaz et al., 2009; Parida et al., 2012; Vashisht et
al., 2008; Wang et al., 2011).
Together with neutralizing antibodies, cell-mediated immunity has been
hypothesized to be a correlate of protection against PRRSV. Variable levels of protection
can be achieved in the absence of neutralizing antibody titers, which leads to the belief that
cell-mediated immunity contributes to protection against PRRSV (Roca et al., 2012; Trus
et al., 2014; Zuckermann et al., 2007). Charerntantanakul et al. (2006) determined the
existence of robust correlations between the percentage of IFN-γ+ cells in PBMC and the
reduction of lung lesions and viremia after PRRSV challenge.

5. Prevention and control
5.1. Diagnosis
PRRSV should be suspected in any herd with reproductive diseases in breeding
swine and/or respiratory disease in pigs of any age; however, the absence of clinical signs
should not rule out PRRSV infection. Differential diagnosis of PRRSV include classical
swine fever virus, cytomegalovirus, hemagglutinating encephalomyelitis virus,
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leptospirosis, parvovirus, porcine circovirus 2, pseudorabies virus, swine influenza virus,
and teschovirus (Zimmerman et al., 2012).
For optimum isolation of PRRSV from clinical samples, both PAM and MARC145 cells are recommended (Yoon et al., 2003). Microscopically, PRRSV antigen can be
visualized in tissue sections of infected animals, such as lung, by either
immunohistochemistry or immunofluorescence using monoclonal antibodies targeting the
N protein (Halbur et al., 1994; Rossow et al., 1995). Commercially available real time
reverse transcription (RT)-polymerase chain reaction (PCR) can be employed for the
detection of PRRSV in serum, semen, tissues, and oral fluids (Prickett et al., 2008; Rovira
et al., 2007).
Serological diagnosis of PRRSV can be accomplished by indirect fluorescent
antibody (IFA) assay, enzyme-linked immunosorbent assay (ELISA), and serum virus
neutralization (SVN) assay. Of these, commercial ELISAs are deemed sensitive, specific,
and easy to use (Rossow, 1998; Yoon et al., 2003).

5.2. Prevention, control, and eradication strategies
PRRSV prevention strategies are geared towards impeding the entry of the virus
into negative herds and the introduction of new viral variants into infected herds. To
achieve this purpose, swine producers may implement one or more protocols, including the
use of quarantine facilities and testing protocols for incoming breeding stock, sanitation
and drying protocols for transport vehicles and incoming suppliers, personnel entry
protocols, and insect control programs (Dee, 2003; Pitkin et al., 2009).
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PRRSV control strategies aim to limit the deleterious effects of PRRSV infection
in the various stages of production. Gilt acclimatization—a process by which replacement
gilts develop immunity to PRRSV prior to their introduction into the breeding herd—can
be achieved by direct contact with infected animals, intentional exposure, or vaccination.
Gilts that undergo the acclimatization process are introduced into the herd when they are
no longer viremic (FitzSimmons and Daniels, 2003). Because vaccine-induced protection
to PRRSV has been deemed weak and/or inconsistent, intentional exposure of gilts can be
achieved by inoculation with serum obtained from viremic animals (FitzSimmons and
Daniels, 2003). Other control strategies include partial depopulation, all-in/all-out pig flow,
and vaccination (Dee, 2003).
Several approaches have been proposed for PRRSV eradication, including whole
herd depopulation-repopulation, test and removal, herd closure, and partial depopulation
(Dee, 2003). Herd closure relies on the ability of the animal to effectively mount an
immune response against—and subsequently eliminate—PRRSV. Due to the persistent
and chronic nature of PRRSV, an extended period of time of at least 200 days is
recommended for herd closure, during which no replacement gilts are allowed entry into
the breeding herd (Linhares et al., 2014; Torremorell et al., 2002).

5.3. Vaccines
Commercial vaccines against PRRSV have been available since 1994. Both killed
vaccines (KVs) and modified-live vaccines (MLVs) can be found in the market; however,
only MLVs were shown to provide effective, albeit variable, levels of protective immunity
against PRRSV (Zuckermann et al., 2007). Due to the insufficient efficacy afforded by
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current vaccines, extensive research has gone into developing novel PRRSV vaccines
capable of eliciting consistent and broad protective immune responses.

5.3.1. Killed, subunit, and vectored vaccines
In the young pig model, a PRRSV-1 KV was shown to afford no protection against
infectious challenge, although the vaccine and challenge strains were 99% homologous at
the level of ORF5 gene sequence (Zuckermann et al., 2007). Furthermore, a PRRSV-1 KV
failed to protect pregnant gilts from the appearance of viremia and clinical signs and the
transplacental infection of piglets after challenge with a heterologous PRRSV-1 strain
(Scortti et al., 2007). Finally, KV-immunized boars showed no change in the onset, level,
and duration of viremia and shedding of virus in semen after infectious PRRSV challenge
(Nielsen et al., 1997). Recently, vaccination with a PLGA nanoparticle-entrapped PRRSV
KV administered intranasally with Mycobacterium tuberculosis whole-cell lysate as an
adjuvant was shown to reduce viremia and viral burden and lesions in lung after
heterologous PRRSV challenge (Binjawadagi et al., 2014).
The efficacy of immunization with baculovirus-expressed GP3, GP5, and N protein
was evaluated by the number of piglets born alive and healthy at the time of weaning. GP3and GP5-immunized sows showed partial protection to homologous challenge, while N
protein-immunized sows did not (Plana Duran et al., 1997). Piglets inoculated with a
recombinant fowlpox-vectored vaccine encoding both ORF3 and ORF5 of PRRSV showed
lower temperature, viremia, and virus load in tonsil, lymph node and lung after homologous
challenge (Shen et al., 2007). Likewise, piglets inoculated with a recombinant adenovirus
vaccine encoding both ORF3 and ORF5 of PRRSV exhibited reduced clinical signs,
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viremia, and lung lesions after homologous challenge (Wang et al., 2009). Both
recombinant attenuated PRV- and transmissible gastroenteritis virus-vectored vaccines
expressing PRRSV GP5 or GP5 and M protein, respectively, have been shown to confer
partial protection against homologous PRRSV challenge in young piglets (Cruz et al.,
2010; Qiu et al., 2005).
Pirzadeh and Dea (1998) demonstrated that while immunization with a plasmid
encoding ORF5 of PRRSV protected piglets from viremia and the development of
macroscopic lung lesions after homologous challenge, vaccination with Escherichia coliexpressed recombinant ORF5-encoded protein did not. Contrarily, Diaz et al. (2013) later
determined that DNA vaccination with a plasmid encoding both ORF5 and ORF6 of
PRRSV could be responsible for an exacerbation of the clinical signs observed after
challenge.

5.3.2. Modified-live vaccines
Benefits associated with PRRSV MLV vaccination include reduction of clinical
signs, rescue in body weight loss, reduced lung lesions, and reduced viral shedding (Cano
et al., 2007; Dwivedi et al., 2011; Linhares et al., 2012). Vaccination of young piglets with
a PRRSV-2 MLV was shown to afford variable levels of protection against heterologous
PRRSV-2 challenge and PRRSV-1 challenge (Park et al., 2015; Park et al., 2014).
Nonetheless, a PRRSV-1 MLV was also proven to provide incomplete cross-protection
against challenge with a homologous virus, suggesting that the degree of genetic
similarity—in this case based on ORF5 genetic sequences—between MLV strain and
challenge isolate may not be a good predictor of vaccine efficacy (Prieto et al., 2008).
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Overall, although MLVs have been shown to protect against clinical disease, they still fail
to prevent PRRSV infection.
PRRSV MLVs are considered ineffective for control and eradication of the virus
and severe PRRSV outbreaks have been shown to occur in MLV-vaccinated farms (Vu et
al., 2017; Wang et al., 2015). Another major limitation of the current MLVs is that they do
not allow serological discrimination between naturally infected and vaccinated animals—
also known as DIVA (differentiating infected from vaccinated animals)—a condition sine
qua non for the control and eradication of most animal diseases (Vu et al., 2013).
Furthermore, the extreme genetic and antigenic variability of the virus coupled with its
ability to rapidly evolve and subvert the innate immune system are a major obstacle for
developing a broadly-protective vaccine against PRRSV (Meng, 2000; Vu et al., 2017).
Finally, because MLVs replicate in the host, there is always a potential for reversion to
virulence (Nielsen et al., 2001).

5.3.3. Approaches to increase the efficacy of vaccines
Several strategies have been attempted to increase the efficacy of PRRSV vaccines.
Mengeling et al. (2003) demonstrated that vaccination with five attenuated strains of
PRRSV-2 did not deliver better heterologous protection than vaccination with a single
strain MLV. A chimeric virus carrying structural proteins from the genetically distinct
PRRSV strains VR-2332 and JA-142 was shown to afford protection against challenge
with both its parental strains. It still remains to be proven that it can protect against strains
or isolates genetically distinct from its parental strains (Sun et al., 2016a). Furthermore,
vaccination with an MLV containing randomly recombined DNA sequences of ORF3,
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ORF4, ORF5, and ORF6 from multiple PRRSV-2 strains did not confer better heterologous
protection than the original MLV (Tian et al., 2015).
Vu et al. (2015) have developed a centralized or consensus PRRSV-2 immunogen
based on 59 full-genome sequences and demonstrated that the immunization by infection
with this synthetic virus was able to accord broader levels of cross-protection than their
reference strain. Sun et al. (2016b) later showed that—unlike other PRRSV strains or
isolates—infection with the consensus PRRSV-2 strain induced type I IFN in vitro.
Recently, a serially-passaged attenuated strain of this consensus PRRSV-2 immunogen
was revealed to maintain the type I IFN-induction phenotype while exhibiting promising
safety and efficacy profiles (Sun et al., 2017).
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Figure 1.1. Schematic representation of the PRRSV genome.
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CHAPTER II
MATERIALS AND METHODS

1. Cells
MARC-145 monkey kidney cells (Kim et al., 1993) were used to propagate and
titrate PRRSV and measure serum viral neutralizing activity. Cells were cultured at 37° C
with 5% CO2 in low glucose Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal bovine serum (FBS), 100 Units/mL of Penicillin, and 100 µg/mL of
Streptomycin (Life Technologies, Carlsbad, CA).
PBMC were cultured at 37° C with 5% CO2 in complete RPMI (cRPMI) media
consisting of RPMI-1640 (GE Healthcare, Little Chalfont, United Kingdom) supplemented
with 10% FBS, 1X of GlutaMAX-I (Life Technologies), 100 Units/mL of Penicillin, and
100 µg/mL of Streptomycin.

2. Antibodies and reagents
The PRRSV-specific monoclonal antibody was purchased from the National
Veterinary Services Laboratory (Ames, IA), the Alexa Fluor 488-conjugated goat antimouse antibody was purchased from Invitrogen (Eugene, OR), and the mouse anti-pig IgG
antibody was purchased from BD Biosciences (San Jose, CA).
The pig IFN-γ enzyme-linked immunospot (ELISpot) assay capture (clone P2G10)
and detection (clone P2C11) antibodies were purchased from BD Pharmingen (San Diego,
CA), the streptavidin-conjugated alkaline phosphatase, Streptavidin-AP, was purchased
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from SouthernBiotech (Birmingham, AL), and the substrate, Vector Blue Alkaline
Phosphatase Substrate, was purchased from Vector Laboratories (Burlingame, CA).

3. Viruses and peptides
The PRRSV strain FL12 was derived from isolate NVLS 97-7895 and recovered
from a full-length infectious cDNA clone (Truong et al., 2004). The PRRSV-1 strain SD0108 was recovered from a cDNA clone kindly provided by Y. Fang, Kansas State University
(Fang et al., 2006). Isolates 1692-98, 21599-00, 46517-00, 16244B (Allende et al., 1999),
3805-00, 43807-00, 18565-01,18066-04 were obtained from the Iowa State University
Veterinary Diagnostic Laboratory (Ames, IA) and the Nebraska Veterinary Diagnostic
Center at the University of Nebraska–Lincoln (Lincoln, NE). The isolate MN184C was
kindly provided by K.S. Faaberg, National Animal Disease Center (Wang et al., 2008). All
viruses had been adapted to grow in MARC-145 cells.
PRRSV full-genome coding sequences for strains FL12 and SD01-08 and isolates
16244B and MN184C were obtained from GenBank. Full-genome coding sequences for
isolates 1692-98, 21599-00, 46517-00, 3805-00, 43807-00, 18565-01, and 18066-04 were
kindly provided by W. Laegreid, University of Wyoming and submitted to GenBank.
Strains or isolates with their respective GenBank accession numbers are presented in Table
2.1.
Synthetic 20-mer peptides with overlapping 10-mer encompassing the entire
sequence of the FL12 structural proteins GP2-5, M, and N were kindly provided by Dr. B.
Kaltenboeck, Auburn University.
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4. Virus propagation and titration
Confluent two-day old MARC-145 cells in 100 mm tissue culture dishes were
infected with PRRSV at a multiplicity of infection of 0.1 in 2 mL inoculums and incubated
for one hour with intermittent rocking every 10 minutes. Subsequently, 10 mL of low
glucose DMEM supplemented with 5% FBS, 100 Units/mL of Penicillin, and 100 µg/mL
of Streptomycin were added. All strains and isolates were grown until approximately 80%
of the cells exhibited significant cytopathic effect (2–4 days), released from the cells by
one freeze-thaw cycle at -80° C, clarified by centrifugation at 3,000 x g for 5 minutes, and
frozen at -80° C in 1 mL aliquots.
Virus titers were determined by endpoint dilution assay in MARC-145 cells. Virus
stocks were diluted 10-fold serially in low glucose DMEM. Each virus dilution was
separately inoculated into eight wells of a 96-well plate containing confluent two-day old
MARC-145 cells at 100 µL per well and incubated for three to four days. IFA was
performed on the cell monolayers. Virus titers were calculated following Reed and
Muench’s method (Reed and Muench, 1938) and expressed as tissue culture infectious
dose 50 (TCID50) per mL.

5. Indirect fluorescence assay
For IFA, MARC-145 monolayers were washed once with phosphate buffered saline
(PBS) and fixed in a cold mixture of acetone/methanol (1:1 v/v) for 10 minutes at room
temperature and air dried. Next, the cell monolayers were washed once with PBS and
incubated with 30 µL of a 1:500 working dilution of the PRRSV-specific monoclonal
antibody in PBS for one hour at 37° C. Cell monolayers were washed three times with PBS,
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followed by incubation with 30 µL of a 1:1000 working dilution of Alexa Fluor 488conjugated goat anti-mouse antibody for one hour at 37° C. After three washes with PBS,
the cell monolayers were examined under an inverted fluorescence microscope for specific
cytoplasmic fluorescence.

6. Animal experiments
All animals were housed and handled following protocols approved by the
Institutional Animal Care Committee of the University of Nebraska–Lincoln. Pigs were
obtained from a swine herd with certified records of absence of PRRSV infection and were
kept in an isolated biosafety level 2 facility. One week acclimation was allowed between
the arrival of the pigs to the facility, at three weeks of age, and the initial inoculation. All
inoculations with PRRSV were performed intramuscularly with 105.0 TCID50 of virus in 2
mL of FBS-free low glucose DMEM. Blood samples were collected from all animals
before infection, and periodically after infection. Serum samples were stored in 1-mL
aliquots at -80° C.

7. Isolation of peripheral blood mononuclear cells
Whole blood was collected into a BD Vacutainer tube with sodium citrate
(Pharmingen, San Diego, CA). 15 mL of whole blood were thoroughly mixed with 15 mL
of PBS+2% FBS and subsequently layered on top of 15 mL of Lymphoprep separation
media (StemCell Technologies, Vancouver, Canada) in a 50-mL SeppMate Tube
(StemCell Technologies) and centrifuged at 2,500 x g at room temperature for 20 minutes.
The PBMC-containing interphase was then transferred into a 50-mL polypropylene
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centrifuge tube and washed once with PBS+2% FBS, after which contaminating red blood
cells (RBCs) were lysed with 5 mL of RBC lysis buffer. Isotonicity was restored with 15
mL of PBS+2% FBS. Next, PBMC were centrifuged at 250 x g for 8 minutes and
resuspended in 10 mL of RPMI-1640 media. A 10 µL aliquot was mixed with 10 µL of
Cellometer AOPI Staining Solution in PBS (Nexcelom Biosciences, Laurence, MA), and
viable cells counted on a disposable hemocytometer with an inverted fluorescent
microscope. Finally, PBMC were centrifuged at 250 x g for 8 minutes and adjusted to 11.5x107 viable cells/mL in RPMI 1640+40% FBS+10% DMSO and frozen in 1-mL
aliquots at -80° C.

8. Enzyme-linked immunospot assay
The ELISpot assay was performed as previously described (Meier et al., 2003).
PVDF membrane 96-well plates were activated with 35% ethanol for 30 seconds, washed
twice with distilled water and once with PBS. Subsequently, wells were coated overnight
with 0.5 µg of anti-pig IFN-γ antibody in 50 µL of PBS. Plates were then washed three
times with PBS and blocked for 2 hours with cRPMI media.
PBMC were rapidly thawed at 37° C and resuspended in 10 mL of warm RPMI1640 media. Viable PBMC were counted using the Cellometer AOPI Staining Solution in
PBS, re-suspended to a concentration of 5x106 cells/mL in cRPMI media, and plated at
5x105 cells/well. For whole virus re-stimulation, PRRSV was diluted to 5,000,000
TCID50/mL in cRPMI media and 100 µL added to each well (final concentration 500,000
TCID50 per well). For peptide re-stimulation, peptide pools were diluted 1:100 in cRPMI
and 100 µL added to each well (final concentration 0.04 nmol per well). Two replicates of
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each sample were plated for each strain/isolate or peptide, and each animal. Mock-infected
MARC-145 supernatant and DMSO diluted 1:100 in cRPMI were used as negative control
for PRRSV and peptide re-stimulation, respectively, and PMA (10 ng/mL) and ionomycin
(1 µg/mL) as positive control. Cells were incubated for 17–20 hours.
Plates were washed with PBS+0.05% Tween-20 (PBS-T20) for 10 minutes, and
further washed three times with PBS-T20. Next, 50 µL of a streptavidin-conjugated antipig IFN-γ antibody was added at a concentration of 2 µg/mL for one hour at room
temperature. Plates were washed six times with PBS-T20 and 50 µL of a working dilution
of 1 µL/mL of Streptavidin-AP was added for 45 minutes at room temperature. Plates were
washed six times with PBS-T20 and multiple times under running distilled water after
which they were developed with a solution of Vector Blue Alkaline Phosphatase Substrate
prepared according to manufacturer instructions for 7–10 minutes. Spots were counted and
analyzed using a CTL ImmunoSpot counter (Cellular Technology Limited, Shaker
Heights, OH).

9. Enzyme-linked immunosorbent assay
PRRSV antibodies in serum were determined at the Nebraska Veterinary
Diagnostic Center using the commercial ELISA IDEXX PRRS X3 Ab Test (IDEXX
Laboratories, Westbrook, ME) according to the manufacturer’s instructions. The status of
each sample was evaluated by the sample-to-positive (S/P) ratio. An S/P ratio ≥ 0.4 was
considered positive.
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10. Serum IFA
MARC-145 cells were seeded into 96-well plates, incubated for 48 hours, after
which half of the rows on the plate were infected with 100 TCID50/well of PRRSV and half
were left uninfected. After 48 hours, plates were washed once with PBS and fixed with
acetone/methanol (1:1 v/v) for 10 minutes, air dried, and stored at -20° C.
Test sera was diluted to 1:20 in PBS and 30 µL of this dilution was transferred to a
PRRSV-infected well and an uninfected well. Plates were incubated for one hour at 37° C
and washed three times with PBS. Next, 30 µL of a 1:500 working dilution of mouse antipig IgG antibody was added and incubated at 37° C for one hour. Plates were washed three
times with PBS and 30 µL of a 1:1000 working dilution of Alexa Fluor 488-conjugated
goat anti-mouse antibody was added and incubated for one hour at 37° C. Finally, plates
were washed three times with PBS and examined on an inverted fluorescence microscope
for specific cytoplasmic fluorescence. A titer ≥ 1:20 was considered to be positive (Nelson
et al., 1994).

11. Serum virus neutralization assay
Neutralizing antibody titers of serum samples against specific strains or isolates of
PRRSV were determined using a fluorescent focus SVN assay as previously described (Wu
et al., 2001). Heat-inactivated sera were diluted two-fold serially in 50 µL of low glucose
DMEM supplemented with 5% FBS on a 96-well plate and incubated with an equal volume
of media containing 100 TCID50 of PRRSV for one hour at 37° C. The contents of each
plate were transferred to a new 96-well plate containing two-day old confluent MARC-145
cells and further incubated for three to four days. The presence of PRRSV was determined
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by IFA. The end point titer was expressed as the reciprocal of the highest serum dilution
that neutralized PRRSV in 2 replicate wells. Absence of neutralizing antibody titer was
considered as 0 for statistical analysis.

12. RNA extraction
RNA from serum was isolated using the QIAamp Viral RNA Mini Kit (Qiagen,
Hilden, Germany) following the manufacturer’s instructions.
For isolation of RNA from tissue samples, 300 mg of lymph node, tonsil, or lung
tissue were homogenized in 3 mL of TRIzol reagent (Life Technologies) in a Bullet
Blender 5 Storm (Next Advance, Averill Park, NY) for five minutes at 4° C. Subsequently,
500 µL of the homogenized sample were mixed with 500 µL of TRIzol reagent and
incubated for 10 minutes at 25° C. Next, 200 µL of chloroform were added and the sample
shaken vigorously for 15 seconds, after which it was incubated for 2-3 minutes at 25° C.
The sample was centrifuged at 12,000 x g for 15 minutes at 4° C. Following, 500 µL of the
aqueous phase were transferred to a new microcentrifuge tube, 500 µL of isopropyl alcohol
were added and incubated for 10 minutes, and centrifuged at 12,000 x g for 10 minutes at
4° C. The supernatant was discarded and the RNA pellet was washed once with 70%
ethanol, centrifuged at 7,500 x g for 5 minutes at 4° C and left to air dry. Finally, the sample
was resuspended in 100 µL of distilled water and incubated at 55–60° C for 10–15 minutes
in a heated block. RNA was quantified using a NanoDrop ND-1000 (Thermo Fischer
Scientific, Waltham, MA) and adjusted to 200 ng/µL.
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13. Real-time RT-PCR
PRRSV viral RNA in plasma and tissue samples was quantified by real-time RTPCR as previously described (Beura et al., 2012). The specific primers and probes are
presented in Table 2.3 and were synthesized by Sigma-Aldrich (Woodland, TX). Real-time
RT-PCRs were performed in 25 µL reaction mixtures containing 5.6 µL of distilled water,
12.5 µL of RT-PCR master mix (Affymetrix, Santa Clara, CA), 1 µL of each primer (final
concentration = 400 nM), 0.5 µL of probe (final concentration = 250 nM), 0.5 µL of MMLV RT (Affymetrix), 0.2 µL of RNAse inhibitor (Affimetryx), and 5 µL of template.
The thermal conditions were as follows: 1 cycle at 50° C for 30 minutes, 1 cycle at 95° C
for 2 minutes, and 45 cycles at 95° C for 15 seconds and 60° C for 60 seconds. Sets of viral
RNA templates with known copy numbers were used to establish the standard curves from
which the RNA copy numbers in the test samples were calculated. Results were reported
as log10 copies per mL for serum or log10 copies per µg of total RNA for tissue samples.
For statistical purposes, samples that had undetectable viral RNA levels were assigned a
value of 0 log10 RNA copies.

14. Lung pathology
Microscopic lung lesions were evaluated blindly by a pathologist. Briefly, sections
were taken from the right apical, cardiac, and dorsal lung lobes for histopathologic
examination. Tissues were fixed in 10% neutral buffered formalin for 1–7 days and
routinely processed and embedded in paraffin in an automated tissue processor. Sections
were cut and stained with hematoxylin and eosin. Lung sections were blindly examined
and given an estimated score of the severity of the interstitial pneumonia: 0 = no
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microscopic lesions, 1 = mild perivascular interstitial pneumonia, 2 = mild perivascular to
diffuse interstitial pneumonia, 3 = moderate diffuse interstitial pneumonia, 4 = severe
diffuse interstitial pneumonia, 5 = severe diffuse interstitial pneumonia with collapse and
filling of the alveoli.

15. Statistical analysis
Differences between the means of two data sets was determined by Student’s t-test.
One-way analysis of variance (ANOVA) was used to evaluate differences between the
means of three or more data sets. Two-way ANOVA was used compare the mean
differences between data sets encompassing two independent variables. Tukey’s multiple
comparison test was employed to evaluate which means amongst a set of means statistically
differ from the rest.
Area under the curve (AUC) was approximated using the trapezoidal rule. The
relationship between two variables was calculated using linear regression analysis. The
coefficient of determination (R2) was used to determine goodness of fit.
Statistical analyses were performed and graphs were generated using GraphPad
Prism version 7 for Mac (GraphPad Software, La Jolla, CA).
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Table 2.1. PRRSV strains and isolates with GenBank accession number.
Strain/Isolate

GenBank Accession No.

FL12

AY545985

1692-98

KY348847

21599-00

KY348850

46517-00

KY348852

16244B

AF046869

3805-00

KY348853

43507-00

KY348851

18565-01

KY348849

MN184C

EF488739

18066-04

KY348848

SD01-08

DQ489311
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Table 2.2. Primers for real-time RT-PCR.
Target
PRRSV-2 3’UTR

Isolate 16244B

Primer/Probe

Sequence (5’ ® 3’)

3UTR44F

ATGTGTGGTGAATGGCACTG

3UTR141R21

GCATGGTTCTCGCCAATTAAA

3UTR84P

TCACCTATTCAATTAGGGCGACCG

16244B15262F

GGCTGGCATTCTTGAGGCAT

16244B15369R

CACGGTCGCCCTAATTGAATA

16244B15323P

CAGTGCCATTCACCACACATTCTTCC
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1. Abstract
Because PRRSV exhibits extensive genetic variation among field isolates,
characterizing the extent of cross-reactivity of immune responses, and most importantly
cell-mediated immunity (CMI), could help in the development of broadly cross-protective
vaccines. We infected 12 PRRSV-naïve animals with PRRSV strain FL12 and determined
the number of IFN-γ SC by enzyme-linked immunospot (ELISpot) assay using ten
PRRSV-2 and one PRRSV-1 isolates as recall antigens. The number of IFN-γ SC was
extremely variable among animals, and with exceptions, late to appear. Cross-reactivity of
IFN-γ SC among PRRSV-2 isolates was broad, and we found no evidence of an association
between increased genetic distance between isolates and the intensity of the CMI response.
Comparable to IFN-γ SC, total antibodies evaluated by IFA were cross-reactive; however,
neutralizing antibody titers could only be detected against the strain used for infection.
Finally, we observed a moderate association between homologous IFN-γ SC and
neutralizing antibodies.
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2. Introduction
PRRSV is the etiological agent of the most important infectious disease of swine
worldwide, causing late-term reproductive failure in sows, sperm abnormalities in boars,
and respiratory illness in young pigs (Collins et al., 1992; Wensvoort et al., 1991).
Widespread in most swine producing countries, PRRSV causes substantial financial losses
to swine producers. In the United States alone, PRRSV-associated losses were estimated
to be at least $664 million (Holtkamp et al., 2013).
PRRSV is an enveloped, positive-sense, single-stranded RNA virus classified
within the genus Porartevirus, family Arteriviridae, order Nidovirales (Adams et al., 2016;
Adams et al., 2017). PRRSV encompasses two species, PRRSV-1, former European or
type 1, and PRRSV-2, former North American or type 2, that share ~65% genomic
sequence identity (Allende et al., 1999; Nelsen et al., 1999).
The PRRSV genome, of approximately 15 kb, encodes 11 ORFs. ORF1a and
ORF1b encode two polyproteins that, when cleaved, yield 14 nsps (Snijder et al., 2013).
Of these, nsp1α, nsp1β, nsp2, nsp4, and nsp11 have been involved in the modulation of the
innate immune response and suppression of type I IFN signaling (Beura et al., 2010). The
structural ORFs ORF2a, ORF3, ORF4 encode the minor surface glycoproteins GP2, GP3,
GP4, respectively, that form a heterotrimer and interact with the cell surface receptor
CD163 (Calvert et al., 2007; Das et al., 2010). Encoded by ORF5, the major glycoprotein
GP5 forms a heterodimer with the M protein encoded in ORF6 (Mardassi et al., 1996).
Although PRSSV viremia can last up to one month PI or more, and persistent
continuous low levels of viral replication in lymphoid tissues can be detected up to 150
DPI or more, the virus is eventually cleared by the host (Allende et al., 2000). This reveals
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that later in the course of infection the pig immune response is competent in removing the
virus from the animal, demonstrating that an appropriate adaptive immune response has
been mounted (Loving et al., 2015). Notwithstanding, the components of the adaptive
immune response that are responsible for such clearance being partially or ill-defined. The
humoral immune response against PRRSV can be detected as early as 7 DPI, when
abundant non-neutralizing antibodies appear. These antibodies are cross-reactive against
heterologous PRRSV isolates (Yoon et al., 1994). Serum neutralizing antibodies only
appear on or after 28 DPI, and have been shown to provide full protection against
homologous challenge when such antibodies attained appropriate concentrations (i.e. titer)
in the circulation; however, titers of cross-neutralizing antibodies are meager and
frequently rare (Lopez et al., 2007; Meier et al., 2003; Osorio et al., 2002; Vu et al., 2011;
Yoon et al., 1994). On the other hand, the PRRSV-specific T cell response has been shown
to be variable over time and among individual pigs, appearing as early as two weeks’ post
infection, but showing a fairly low initial onset (Meier et al., 2003; Xiao et al., 2004).
Previous studies have evaluated the importance of the IFN-γ SC response and its
correlation to protective immunity, and several authors have concluded that an adequate
correlation exists between the IFN-γ SC response and protective immunity
(Charerntantanakul et al., 2006; Lowe et al., 2005; Meier et al., 2004; Zuckermann et al.,
2007). With exceptions, only homologous strains have been used to evaluate CMI
responses, and a comprehensive evaluation of the cross-reactivity of T cell responses
against PRRSV is still lacking.
PRRSV genetic heterogeneity has been thoroughly documented, and it has been
hypothesized that antigenic relatedness of the strains or isolates used for immunization and
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challenge plays a major role in determining their immunogenic effectiveness, thus
constituting a central factor towards the development of more broadly protective vaccines
(Meng, 2000; Murtaugh et al., 2010). Because a combination of neutralizing antibody and
T cell responses seems to be responsible for protective immunity against PRRSV, we were
interested in evaluating how genetic diversity, and hence antigenic diversity, played into
the cross-reactivity of cell-mediated and humoral immune responses.
To that effect, we synchronously infected a group of 12 animals with our reference
pathogenic strain FL12 and assessed the kinetics of the PRRSV immune response
throughout an appropriate period of convalescence (Fig. 3.1). In parallel, 12 animals were
left uninfected. We measured total and neutralizing antibodies as well as IFN-γ SC
responses sequentially assessed in all cases against the homologous infecting strain as well
as against an array of increasingly divergent (thus, increasingly heterologous) PRRSV
isolates (Table 3.1). The study allowed us to evaluate and compare the homologous (i.e.
against infecting strain) response in each of the 12 animals and characterize the crossreactivity towards heterologous divergent isolates, thus providing a description of how
these parameters may associate.

3. Results
3.1. Variability of T cell responses
FL12-specific IFN-γ SC were detected as early as 14 DPI in some animals, with
most animals showing a highly variable number of IFN-γ SC at 28 and 42 DPI, after which
variability could still be observed, but at a reduced rate. We observed fundamentally
distinct IFN-γ SC kinetics among the FL12-infected animals (Fig. 3.2A).
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Two animals (301 and 314) showed an increase of PRRSV-specific IFN-γ SC
peaking at 42 DPI in very high numbers, after which the numbers slowly declined. While
the number of IFN-γ SC of animal 314 was low throughout the first 28 DPI, animal 301
showed an earlier cell-mediated response, starting at 14 DPI. Another group of animals
(299, 304, 323, and 358) showed a weaker biphasic response, with a first peak occurring
at 28 DPI and a second peak at 63 DPI. A third subset of animals (317, 321, 325, and 330)
demonstrated an even weaker response, in most cases only present in very small numbers
at 28 and 42 DPI, but with a steady climb, peaking at 77 DPI. The CMI kinetics of two
animals (333 and 315) did not fit any of the aforementioned patterns, animal 315 showed
a steady climb of IFN-γ SC until 63 DPI that diminished by 77 DPI, while animal 333
experienced two peaks at 42 and 77 DPI. With the exception of animal 301, and regardless
of the pattern observed, all animals at 77 DPI appeared to reach a similar number of IFNγ SC.
To further evaluate the overall variability over the entire duration of the experiment,
we calculated the AUC for the number of IFN-γ SC from 0 to 77 DPI (Fig. 3.2B). The two
animals with the fastest and strongest responses (301 and 314) had, in turn, the highest
calculated AUC, while the four animals with the slowest and weakest kinetics had the
smallest calculated AUC. The remaining animals, including those representative of the
biphasic response, had a calculated AUC in between the aforesaid animals.
Similar variability of T cell responses could also be observed when we evaluated
the IFN-γ SC response using nine other PRRSV-2 isolates as recall antigen, but not with
the PRRSV-1 strain SD01-08 (Fig. 3.3). We did not detect any IFN-γ SC in uninfected
animals throughout the course of our study.
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3.2. Nucleotide pairwise distance between FL12 and heterologous strains and isolates
Coding genome-wide sequences of FL12, nine heterologous PRRSV-2 isolates, and
the PRRSV-1 strain SD01-08 were aligned using MUSCLE (Edgar, 2004). Calculated
nucleotide pairwise distances are presented in Table 3.1. Using MEGA7, a phylogenetic
tree was inferred using the maximum likelihood method and is presented in Figure 3.4
(Kumar et al., 2016; Tamura and Nei, 1993).
Three PRRSV-2 isolates exhibited a low calculated nucleotide pairwise distance to
FL12: 1692-98 and 21599-00 at 5.02%, and 46517-00 at 6.36%. Three PRRSV-2 isolates
had a moderate calculated nucleotide pairwise distance to FL12: 16244B at 9.66%, 380500 at 9.71%, and 43807-00 at 10.11%. Another three PRRSV-2 isolates had a high
calculated nucleotide pairwise distance to FL12: 18565-01 at 12.65%, MN184C at 14.32%,
and 18066-04 at 14.48%. Finally, the PRRSV-1 isolate SD01-08 had a genome-wide
calculated nucleotide pairwise distance of 36.72% to FL12.

3.3. Cross-reactivity of T cell responses
To evaluate the cross-reactivity of T cell responses against PRRSV we used the
homologous strain FL12, nine other PRRSV-2 isolates of varying genetic distance, and one
PRRSV-1 isolate as recall antigen. A two-way ANOVA was performed to determine the
effect of PRRSV isolate used as recall antigen on the number of IFN-γ SC (Fig. 3.5A).
Although there was a statistically significant interaction between the effects of PRRSV
isolate and the number of IFN-γ SC, simple main effects analysis showed that PRRSV-2
isolates induced significantly stronger T cell responses than the PRRSV-1 strain SD01-08,
but no significant differences were detected among PRRSV-2 isolates.
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Further analyses demonstrated no significant differences between SD01-08 and all
PRRSV-2 isolates at 14 and 28 DPI (with the exception of MN184C at 28 DPI) and, starting
at 28 DPI, and through every other time point, all PRRSV-2 isolates produced a
significantly higher number of IFN-γ SC than SD01-08. We were able to observe that
FL12-, MN184-, and 16244B-re-stimulated PBMC showed a number of IFN-γ SC
significantly higher than other PRRSV-2 isolates at 42 and 63 DPI. Finally, FL12- and
MN184C-re-stimulated PBMC had higher numbers of IFN-γ SC than the isolates 3805-00
and 18565-01 at 77 DPI.
To additionally evaluate T cell cross-reactivity, we calculated the mean and
standard error of the AUC for each isolate used as recall antigen and performed a one-way
ANOVA (Fig. 3.5B). There was a significant difference between PRRSV isolates used as
recall antigens; however, there was no significant difference among PRRSV-2 isolates.
PRRSV-2 isolates recalled a higher number of IFN-γ SC than the PRRSV-1 strain SD0108. Extensive cross-reactivity was not only observed when we evaluated as a group the
mean number of IFN-γ SC against each of the ten PRRSV-2 isolates (including FL12), but
also while examining the T cell responses of each individual animal (Fig. 3.6).

3.4. Isolate genetic distance and T cell responses
To study the relationship between isolate genetic distance and T cell responses we
determined the mean IFN-γ SC number for each PRRSV-2 isolate and fit a linear regression
model against the previously calculated nucleotide pairwise distance of said isolate to FL12
(Fig. 3.7A–E). Our results indicate that changes in genetic distance are not associated with
changes in the mean number of isolate-specific IFN-γ SC at 14, 28, 42, 63 and 77 DPI.
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To further evaluate this relationship over the entire course of the assay we
determined the mean AUC of IFN-γ SC for each PRRSV-2 isolate and fitted a linear
regression model with the calculated nucleotide pairwise distance of said isolate to FL12
(Fig. 3.7F). No significant association could be found between the mean AUC of IFN-γ SC
and calculated nucleotide pairwise distance of the isolate.

3.5. Total and neutralizing antibody responses
Five of the ten PRRSV-2 isolates were selected to evaluate the total and neutralizing
antibody response. Together with the homologous strain FL12, we included low distance
isolates 1692-98 and 21599-00, medium distance isolate 16244B and high distance isolate
18565-01. The total antibody responses, evaluated by IFA, was deemed negative at 0 DPI
for all animals (< 1:20) and all isolates tested. Starting at 28 DPI, and at 63 and 77 DPI all
animals were positive by IFA (≥ 1:20) against all five isolates (Fig. 3.8A).
Neutralizing antibodies against isolate FL12 were determined by SVN and were
absent at 0 and 28 DPI. Homologous titers could be detected starting at 63 DPI and
continued to rise until 77 DPI (Fig. 3.8B). Subsequently, we sought to determine whether
neutralizing antibody titers could be obtained against the four heterologous isolates. We
tested the sera obtained at 77 DPI and found that, with very few exceptions, no neutralizing
antibody titers could be detected against 1692-98, 21599-00, 16244B and 18565-01 (Fig.
3.8C). A weak (1:4) neutralizing antibody titer was found in one pig against isolate 2159900 and in another pig against 16244B.
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3.6. Association between T cell and neutralizing antibody responses
As both neutralizing antibody and IFN-γ SC seem to appear at later time points of
the PRRSV infection, we were interested in determining whether there was an association
between these two variables. At 63 and 77 DPI, we paired the homologous neutralizing
antibody titer against FL12 for each animal with its respective number of FL12-specific
IFN-γ SC and fitted a linear regression (Fig. 3.9). Our results indicate that at 63 DPI 34.86%
of the variation of neutralizing antibody titers can be explained by the variation in the
number of IFN-γ SC, while this value increases to 51.64% at 77 DPI. In the absence of
neutralizing antibody titers, both at earlier time points and against heterologous isolates,
no further calculations could be conducted.

4. Discussion
Since PRRSV was first reported in the late 1980’s, our understanding of its
pathogenesis and immunology have grown steadily; however, we are still lacking a broadly
cross-protective PRRSV vaccine. Our past research has demonstrated that appropriate
concentrations of neutralizing antibodies can provide sterilizing immunity against PRRSV
challenge, but these neutralizing antibodies are seldom cross-reactive (Lopez et al., 2007;
Osorio et al., 2002; Vu et al., 2011). The cross-protection afforded by currently available
commercial vaccine strains is at least that of the field isolates from which they were
derived, but it has become clear that there is a great need for improvement in the breadth
of this cross-protection (Renukaradhya et al., 2015; Shi et al., 2010a). For any vaccine,
sterilizing immunity is the ultimate goal, and in PRRSV this can be accomplished through
neutralizing antibodies. Due to our limited knowledge on the nature and kinetics of
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neutralizing antibodies, and how T cell help contributes to their appearance, we believe
this work could provide new directions for the design of cross-protective PRRSV vaccines.
Because our understanding of CMI against PRRSV is scarce, we were not only
interested in determining how PRRSV-specific T cells could associate with neutralizing
antibodies, but also to determine how T cells cross-reacted against other field isolates, and
whether the isolate heterogeneity, determined by its genome-wide calculated nucleotide
pairwise distance to the challenge isolate, could be linked to varying levels of crossreactivity. We have recently shown that minimizing the calculated nucleotide pairwise
distance between immunization and challenge isolates provided an unprecedented level of
cross-protection (Vu et al., 2015), hence we hypothesized that increased calculated
nucleotide pairwise distance as a determinant of antigenic variability and heterogeneity of
field isolates could be negatively associated to CMI.
Our study demonstrates that an outbred population of pigs infected with a PRRSV2 isolate shows a highly variable IFN-γ SC response among individual animals. In apparent
contrast to what was previously described for PRRSV-2 infection by Xiao et al. (2004),
half of our 12 FL12-infected animals had high homologous T cell responses at 28 DPI
(>115 IFN-γ SC/106 PBMC). Furthermore, we observed that one of our animals (301) had
high homologous and heterologous T cell responses at 14 DPI. Authors have described the
PRRSV-specific T cell response as weak and slow; however, our findings reveal that
individual animals can potentially achieve high numbers of PRRSV-specific T cell
responses as early as 14 DPI. It was previously shown that inoculation with virulent
PRRSV elicits a higher number of IFN-γ SC than inoculation with a modified live vaccine
both in piglets and finisher pigs (Klinge et al., 2009). When comparing our results to
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virulent PRRSV inoculation, and those of commercially available MLV immunization, we
further appreciate the fact that virulent PRRSV seems to elicit a stronger CMI than MLV
(Meier et al., 2003; Xiao et al., 2004; Zuckermann et al., 2007). Moreover, it could be
hypothesized that the extreme variability observed among CMI responses in individual
animals could be responsible for the variable protection observed against PRRSV
challenge. The host and pathogen factors behind this variability are yet to be understood.
In our study we evaluated CMI cross-reactivity against an array of genetically
diverse PRRSV-2 isolates and one PRRSV-1 isolate. Our results indicate that T cells from
FL12-infected animals can recognize other PRRSV-2 isolates and secrete IFN-γ in
response to them. The overall kinetic of the T cell responses to all PRRSV-2 isolates were
not significantly different between PRRSV-2 isolates; however, SD01-08, a PRRSV-1
strain, elicited a significantly lower T cell response. Such cross-reactivity is not surprising,
as T cell cross-reactivity has been documented for other pathogens. McMaster et al. (2015)
have demonstrated the existence of cross-reactive T cells against influenza A virus, while
these cross-reactive T cells were shown to provide cross-protection against heterologous
challenge, with reduced morbidity and mortality in mice, they did so in the presence of a
limited neutralizing antibody cross-reactivity. Much alike what has been previously
hypothesized for PRRSV by Zuckermann et al. (2007), the authors claim that protection
from influenza A virus challenge was afforded by T cells. T cell cross-reactivity was also
reported at the virus, protein, and peptide level between members of the
Alphaherpersvirinae subfamily, while T cell cross-reactive peptides have been described
between unrelated viruses such as human papillomavirus and coronavirus and M. bovis
bacillus Calmette-Guérin and poxviruses (Jing et al., 2016; Mathurin et al., 2009; Nilges
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et al., 2003). Because the number of potential peptide antigens surpasses the number of T
cell receptors available by many orders of magnitude, it can be argued that T cells are only
able to provide comprehensive immune coverage if each one of them is capable of
recognizing many peptides (Sewell, 2012). However, our results are in sharp contrast to
what has been previously described for PRRSV-1. When a virulent PRRSV-1 isolate was
inoculated into pigs and PBMC isolated and stimulated in vitro with the homologous isolate
and a heterologous isolate of calculated nucleotide pairwise distance of 12.5%, a significant
reduction of IFN-γ SC was found to occur in the presence of the heterologous virus
stimulation, when compared to the homologous virus. The authors argue that this could be
due to the different ability of these strains to inhibit IFN-γ T cell responses, or due to
different antigenicity of T cell epitopes (Diaz et al., 2012).
Our findings regarding antibody-mediated immunity against PRRSV confirm what
other authors have described: the total antibody response against PRRSV is broadly
reactive and early to occur; however, it is known that these antibodies do not mediate
protection against infection (Lopez and Osorio, 2004). We were not able to detect any
neutralizing antibodies at 28 DPI; conversely, at 63 DPI all but one animal showed
neutralizing antibody titers against FL12, and at 77 DPI all animals did, and in many cases,
these titers were higher. We were not able to detect the presence of neutralizing antibodies
against heterologous PRRSV isolates. Our observation is different from what MartinezLobo et al. (2011) reported for PRRSV-1, where the authors describe the presence of crossreactive neutralizing antibody titers. This divergent observation might be due to the nature
of the antisera used in the neutralization assay, while Martinez-Lobo et al. (2011) used
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hyperimmune antisera obtained from pigs that were repeatedly immunized with PRRSV,
we used convalescent antisera obtained from pigs that were exposed only once to the virus.
IFN-γ SC as measured by the ELISpot assay exhibit a behavior comparable to that
of the total antibody response against PRRSV. Neutralizing antibodies are a subset of the
total antibody response, similarly, it is possible that a T cell subset could be primarily
responsible for providing protection against PRRSV infection. Because we evaluated the
PRRSV CMI using the widely accepted IFN-γ ELISpot assay, our results are not without
limitations. The techniques available in the field of swine immunology are not as
comprehensive or precise as those available for other species, and there is a known
necessity to develop a swine T cell biology toolkit (Loving et al., 2015). Further
characterization of T cell subsets and cytotoxicity will require the usage of multi-color flow
cytometry, already implemented for the study of classical swine fever and influenza A virus
in swine, in combination with tetramer staining, previously shown for foot and mouth
disease virus (Franzoni et al., 2013a; Franzoni et al., 2013b; Gerner et al., 2015; Patch et
al., 2011; Talker et al., 2015; Talker et al., 2016). Further understanding of the major
histocompatibility molecules of swine, the SLA, including the distribution within an
outbred population and the contribution to adaptive immune responses, will also be vital
to further evaluate swine immunity against PRRSV.
Finally, we demonstrate a low to moderate association between the number of IFNγ SC and the magnitude of the neutralizing antibody response. This association could only
be evaluated for the homologous strain FL12, as other isolates failed to elicit any
neutralizing antibody titers. However, our data suggests that between 30 and 50% of the
variation of neutralizing antibody titers can be explained by variation in IFN-γ SC. Due to
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the lack of cross-reactivity of neutralizing antibody responses, the value of this contribution
cannot be stated, as even animals with homologous neutralizing antibody titers of 1:64 or
1:128 showed no ability of cross-neutralizing genetically related isolates. It is extensively
documented that antigen-activated B cells establish interactions in the lymph node that
allow them to receive helper signals from antigen-activated CD4+ T cells. Such
interactions allow for class switch and affinity maturation (De Silva and Klein, 2015;
Kurosaki et al., 2015). Notwithstanding, studies conducted in measles-vaccinated patients
demonstrated the independence between humoral and cellular immune responses (Dhiman
et al., 2005; Jacobson et al., 2012). As previously discussed, further analysis into the
subtypes of T cells involved in PRRSV immunity could provide a stronger biological or
mathematical association between the appearance and progression of neutralizing
antibodies and T cells.
Overall, our results could be interpreted in two distinct ways. On the one hand, it
could be argued that due to the number of IFN-γ SC being not significantly different
amongst PRRSV-2 isolates, T cells play no major role in mediating cross-protection. On
the other hand, it could be hypothesized that, similarly to what has been described for
influenza, T cells react against a broad spectrum of PRRSV-2 PRRSV isolates, contributing
to partial levels of cross-protection against heterologous isolate infection (Sridhar, 2016).
We prefer the latter hypothesis. Furthermore, we favor the idea that, very much like
universal influenza vaccines, broadly protective PRRSV vaccines could rely on the concept
of “heterosubtypic” immunity, in which T cell-mediated immune responses targeting
conserved PRRSV epitopes would confer protection against infection and disease.
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Table 3.1. Calculated nucleotide pairwise distance (%) between PRRSV strains and isolates.
FL12

1692-98 21599-00 46517-00

16244B

3805

43807

18565-01 MN184C 18066-04 SD01-08

FL12

-

5.02

5.02

6.36

9.66

9.71

10.11

12.65

14.32

14.48

36.72

1692-98

5.02

-

5.2

6.28

9.61

9.57

10.01

12.46

14.07

14.2

36.59

21599-00

5.02

5.2

-

5.42

10.01

10.05

10.59

12.61

14.27

14.47

36.47

46517-00

6.36

6.28

5.42

-

10.1

9.79

10.65

12.4

14.33

14.48

36.64

16244B

9.66

9.61

10.01

10.1

-

5.75

3.64

11.96

13.35

13.49

36.37

3805-00

9.71

9.57

10.05

9.79

5.75

-

6.07

12

13.44

13.54

36.71

43807-00

10.11

10.01

10.59

10.65

3.64

6.07

-

12.28

13.77

13.9

36.47

18565-01

12.65

12.46

12.61

12.4

11.96

12

12.28

-

8.31

8.55

36.94

MN184C

14.32

14.07

14.27

14.33

13.35

13.44

13.77

8.31

-

0.52

36.92

18066-04

14.48

14.2

14.47

14.48

13.49

13.54

13.9

8.55

0.52

-

36.95

SD01-08

36.72

36.59

36.47

36.64

36.37

36.71

36.47

36.94

36.92

36.95

-
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Figure 3.1. Experimental design of cross-reactivity study. Chronology of animal
experiment. After an acclimatization period of one week, animals were infected with
PRRSV-2 strain FL12 (n=12) at 0 DPI (q) or left uninfected. White circles () indicate
times at which humoral and cellular immune responses were assessed. Black circles ()
indicate times at which only cellular immune responses were determined.

66

67
Figure 3.2. Kinetics of homologous IFN-γ SC in individual animals infected with PRRSV
strain FL12. (A) FL12-specific IFN-γ SC were detected in PBMC by ELISpot assay at the
indicated times. (B) AUC of IFN-γ SC were calculated using the trapezoidal rule.
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Figure 3.3. Kinetics of IFN-γ SC responses against heterologous PRRSV strains and
isolates in individual animals. (A–J, Top) Isolate-specific IFN-γ SC were detected in
PBMC by ELISpot assay at the indicated times. (A–J, Bottom) AUC of IFN-γ SC were
determined using the trapezoidal rule.
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Figure 3.4. Phylogenetic tree of PRRSV strains and isolates. The phylogenetic tree was
inferred using the maximum likelihood method. The tree is drawn to scale, with branch
lengths measured in the number of substitutions per site.
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Figure 3.5. Evaluation of IFN-γ SC cross-reactivity in the context of PRRSV infection. (A)
The mean and standard error IFN-γ SC number was calculated for each PRRSV strain or
isolated used as recall antigen and the kinetics analyzed by repeated measures two-way
ANOVA. (B) The IFN-γ SC AUC mean and standard error for each isolate was calculated
and analyzed by one-way ANOVA.
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Figure 3.6. Kinetics of IFN-γ SC responses against heterologous PRRSV strains and
isolates in individual animals. (A–L, Top) Isolate-specific IFN-γ SC were detected in
PBMC by ELISpot assay at the indicated times. (A–L, Bottom) AUC of IFN-γ SC were
determined using the trapezoidal rule.
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Figure 3.7. Analysis of calculated nucleotide pairwise distance to FL12 and IFN-γ SC
responses. (A–E) For every time point the mean IFN-γ SC for each PRRSV-2 isolate was
calculated and fitted a linear regression against the calculated nucleotide pairwise distance
of said isolate to FL12. (F) A linear regression was fitted between the mean AUC for each
PRRSV-2 isolate and its calculated nucleotide pairwise distance to FL12.
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Figure 3.8. Evaluation of humoral immune responses after infection with PRRSV. (A)
Antibody responses against FL12, 1692-98, 21699-00, 16244B, and 18565-01 were
evaluated by IFA test. A titer ≥ 1:20 was considered positive. (B) Neutralizing antibody
titers against FL12 were determined by SVN and results are expressed as the log2 of the
reciprocal of the largest dilution of serum that inhibited the development of virus in cell
culture. (C) Neutralizing antibody titers against 1692-98, 21599-00, 16244B, and 1856501 were determined at 77 DPI.
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Figure 3.9. Correlation between neutralizing antibody titers and the number of IFN-γ SC
against FL12. A linear regression was fitted between the FL12-specific IFN-γ SC for each
animal, and their respective neutralizing antibody titers at 63 (A) and 77 (B) DPI. R2 values
are indicated.
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CHAPTER IV
INFECTION OF NAÏVE PIGS WITH PORCINE REPRODUCTIVE AND
RESPIRATORY SYNDROME VIRUS AFFORDS CROSS-PROTECTION TO
SUBSEQUENT CHALLENGE WITH A HETEROLOGOUS ISOLATE
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1. Abstract
PRRSV genetic and antigenic variation are considered a major cause behind the
incomplete—sometimes limited—cross-protection observed in vaccinated or infected
animals to posterior challenge. To circumvent this, many swine producers implement
replacement gilt acclimation protocols infecting naïve animals with live virus obtained
from viremic animals in their respective farms. To ascertain the contribution of the humoral
and cell-mediated immune responses to cross-protection we infected 12 naïve animals with
PRRSV-2 strain FL12 and challenged them 77 days later with the heterologous isolate
16244B. A control group of 12 animals was left uninfected until 77 DPI and challenged in
a similar fashion. After challenge, the IFN-γ SC response in FL12-infected animals
experienced a modest cross-reactive boost. Neutralizing antibody titers against 16244B
were not detected prior to challenge, but rapidly emerged by 14 days post-challenge (DPC).
Cross-reactive neutralizing antibodies against other heterologous PRRSV-2 isolates were
also detected. Good cross-protection to challenge was observed, viremia post-challenge
(PC) was greatly reduced, and tissue viral quantification, and microscopic lung lesions
were modestly, albeit significantly, reduced too. The previously uninfected control group
showed a quick and cross-reactive cell-mediated response against PRRSV-2, but no
neutralizing antibodies after challenge were identified in these animals.
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2. Introduction
PRRSV, a disease characterized by reproductive failure in sows and respiratory
illness in young pigs, appeared in the late 1980’s and early 1990’s in North America and
Europe (Collins et al., 1992; Wensvoort et al., 1991). Since its emergence, it has spread to
most swine-producing countries, causing significant financial losses to the swine industry.
PRRSV-associated financial losses in the United States alone are estimated to be at least
$664 million per year (Holtkamp et al., 2013).
Historically, PRRSV was classified into two distinct genotypes: type 1 or European
and type 2 or North American; however, the new taxonomy of the family Arteriviridae
classifies PRRSV within the genus Porartevirus and divides it into two different species,
PRRSV-1 and PRRSV-2, encompassing the previous genotypes (Adams et al., 2016;
Adams et al., 2017). Genome-wide analysis reveals that only 55-70% nucleotide and 5080% amino acid similarity is shared between PRRSV-1 and PRRSV-2 (Forsberg, 2005).
The PRRSV virion is enveloped, pleomorphic, with an average diameter of 58 nm,
and its genome consists of a single positive strand of RNA of approximately 15 kb
(Spilman et al., 2009). Of the 11 PRRSV ORFs, the large replicase polyprotein ORF1a/b
(and its truncated version ORF1a’), located in the 5’-proximal three-quarters of the
genome, encodes four distinct pp products that are co-translationally and posttranslationally processed into 16 distinct nsps by virally-encoded proteases (Kappes and
Faaberg, 2015). The PRRSV structural proteins are encoded by the eight 3’-proximal ORFs
contained within six sg mRNAs (Snijder et al., 2013).
Infection with PRRSV is chronic and persistent: viremia can be detected up to a
month PI or more, and viral replication in lymphoid tissue can be detected up to 150 PDI
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or more; nonetheless, the host eventually eliminates the virus (Allende et al., 2000; Wills
et al., 1997b). Herd stabilization and closure protocols, in which PRRSV-positive herds
eliminate the virus by preventing the entry of PRRSV-naïve animals for extended periods
of time further illustrate the existence of an efficacious anti-PRRSV immune response
(Linhares et al., 2014; Torremorell et al., 2002).
Significant effort has gone into understanding the immune mechanisms involved in
clearing PRRSV from the host. Non-neutralizing antibodies against PRRSV can be
detected as early as 7 DPI. While it is widely accepted that these early non-neutralizing
antibodies do not mediate protection against the virus, their role in mediating ADE both in
vitro and in vivo is controversial (Delputte et al., 2004; Yoon et al., 1994; Yoon et al., 1997;
Yoon et al., 1996). Neutralizing antibodies, which only appear on or after 28 DPI, have
been shown to deliver full homologous protection against PRRSV (Lopez et al., 2007;
Meier et al., 2003; Osorio et al., 2002). Nevertheless, PRRSV continues to replicate in
lymphoid tissue even in the presence of neutralizing antibodies (Lopez and Osorio, 2004).
Although cross-neutralizing antibodies have seldom been detected, and in very low titers,
it has been proved that hyperimmunization or multiple exposures to PRRSV can induce
broadly neutralizing antibodies against PRRSV (Kim et al., 2007; Martinez-Lobo et al.,
2011; Robinson et al., 2015; Vu et al., 2011). While T cell responses, particularly IFN-γ
SC responses, against PRRSV are slow and weak to appear, they are deemed an important
mediator of heterologous cross-protection (Charerntantanakul et al., 2006; Lowe et al.,
2005; Meier et al., 2003; Xiao et al., 2004; Zuckermann et al., 2007).
Solid homologous protection can be achieved against PRRSV; however, the highly
variable nature and constant evolution of the PRRSV genome constitute an obstacle for
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achieving effective cross-protective immunity (Lager et al., 1997; Lopez et al., 2007; Vu
et al., 2017). Whole-genome genetic difference between PRRSV-1 and PRRSV-2 is
approximately 40%. Diversity, based on ORF5 sequence identity, can be as large as 21%,
within PRRSV-2 and 30% within PRRSV-1 (Murtaugh et al., 2010). Incomplete crossprotection is offered by MLVs, which have been shown to reduce clinical signs, body
weight loss, lung lesions, and viral shedding, but not prevent infection (Cano et al., 2007;
Dwivedi et al., 2011; Linhares et al., 2012). Because of the moderate effectiveness of
MLVs, live virus inoculation—obtained from viremic animals within the herd—may be
used for gilt acclimatization (FitzSimmons and Daniels, 2003). Due to the genetic and
antigenic variability of PRRSV, we were interested in assessing the level of crossprotection afforded by previous PRRSV infection against heterologous challenge, while
evaluating the cellular and humoral immune responses.
To determine the level of heterologous cross-protection afforded by prior exposure
to PRRSV we infected a group of three-week old pigs with PRRSV strain FL12 (n=12)
while a group of pigs (n=12) was left uninfected. Subsequently, 77 days later we challenged
all animals with the heterologous PRRSV isolate 16244B (Fig. 4.1). Before and after
challenge, we measured total and neutralizing antibodies as well as IFN-γ SC responses
sequentially assessed in all cases against the original infection strain, FL12, the challenge
isolate, 16244B, and an array of divergent PRRSV isolates. To assess the level of crossprotection afforded by prior exposure to PRRSV strain FL12 we determined the level of
viremia for 14 days PC, the tissue viral load at 14 days DPC, and the microscopic lung
pathology at 14 DPC. The study allowed us to evaluate the cross-protection afforded by
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prior PRRSV exposure and characterize the cellular and humoral immune responses that
mediate it.

3. Results
3.1. Cellular immune responses after heterologous challenge in FL12- infected animals
Immediately before challenge, at 77 DPI, the number of FL12-specific IFN-γ SC
for most animals was between 200 and 400, apart from animal 301, which was slightly
higher (Fig 4.2A). 16244-specific IFN-γ SC were between 100 and 300 for most animals,
except 301 and 314 which were higher (Fig. 4.2B). Four animals (314, 315, 321, and 299)
had increased numbers of FL12- and 16244B-specific IFN-γ SC by 7 DPC, and while three
experienced a slight decline at 14 DPC, those of animal 299 continued to climb. On the
contrary, five animals (304, 323, 325, 333, and 358) showed a reduction in FL12- and
16244B-specific IFN-γ SC by 7 DPC, followed by an increase at 14 DPC. Animal 301—
that unexpectedly died 7 DPC due to causes not associated with this study—exhibited an
abrupt decline in both FL12- and 16244B-specific IFN-γ SC by 7 DPC. Animal 317
displayed a continuous decline at 7 and 14 DPC of FL12-specific IFN-γ SC; however, the
number of 16244B-specific IFN-γ SC showed a slight increase by 14 DPC. Finally,
although animal 330 displayed a static number of FL12-specific IFN-γ SC from 0 through
14 DPC, the number of 16244B-specific IFN-γ SC was down at 7 DPC and back up again
by 14 DPC. Equivalent variability was observed in all animals when we determined the
number of isolate-specific IFN-γ SC using eight heterologous PRRSV-2 isolates and one
PRRSV-1 strain (Fig. 4.3).
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To determine the extent of cross-reactivity after challenge, individual data sets for
each animal and each strain or isolate were combined (Fig 4.4A). Two-way ANOVA of
these data showed that in most cases the isolate-specific IFN-γ SC number was not
significantly different among PRRSV-2 strains and isolates. The number of IFN-γ SC
specific for of SD-01-08 was shown to be significantly lower than that of FL12, 16244B,
18565-01, and MN184, but not the remaining PRRSV-2 isolates. When evaluating the
isolate-specific AUC of IFN-γ SC after challenge (Fig 4.4B), FL12 was found to recall
higher IFN-γ SC responses than 21599-00, 43807-00, and 18066-04. Furthermore,
MN184C was found to recall higher IFN-γ SC responses than 3805-00, and both FL12 and
46517-00 were found to recall a greater number of IFN-γ SC than SD01-08.

3.2. Humoral immune responses after heterologous challenge in FL12-infected animals
The presence of anti-PRRSV antibodies was assessed with the commercially
available ELISA IDEXX PRRS X3 Ab Test. All animals were PRRSV seropositive (i.e.
an S/P ratio ≥ 0.4) prior to challenge, at 0 DPC, and after challenge, at 14 DPC (Fig. 4.5A).
Neutralizing antibodies against FL12 were present in variable quantities in all
animals at 0 DPC (Fig. 4.5B), but only one animal had a meager 1:4 cross-neutralizing
antibody titer against isolate 16244B immediately before challenge (Fig. 4.5C). Two weeks
after challenge we observed increased anti-FL12 neutralizing antibody titers in all animals,
but also that nine out of 11 animals had developed neutralizing antibodies against isolate
16244B. Of these, six had neutralizing antibody titers of 1:4, while three had titers of 1:8
or more. Moreover, of the nine animals that developed neutralizing antibodies against
isolate 16244B, five also developed titers against isolate 1692-98, and four against isolate
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21599-00 (Fig. 4.5D–E). These titers oscillated between 1:4 and 1:32. Finally, we detected
a neutralizing antibody titer of 1:16 in one animal against isolate 18565-01 (Fig 4.5F).

3.3. Cross protection against heterologous challenge
After challenge, nine animals in the FL12-infected group showed low levels of
viremia at 3 DPC and only one animal remained viremic by 7 DPC (Fig. 4.6A). At 10 and
14 DPC all animals in the FL12-infected group were viremia free. All 12 animals in the
initially uninfected group were viremic starting at 3 DPC and through 14 DPC. Uninfected
control animals developed high viremia, peaking at 7 DPC, and still present by 14 DPC. A
significant reduction in viremia in the FL12-infected group was demonstrated by repeated
measures two-way ANOVA. Additionally, the AUC of viremia, calculated using the
trapezoidal rule, was significantly reduced in the FL12-infected group (Fig. 4.6B).
When compared to the uninfected control group, viral RNA quantification in lymph
node, tonsil, and lung were significantly lower in the FL12-infected group after challenge
(Fig. 4.7). Additionally, 16244B-specific viral RNA could be detected in only two animals
in tonsil, and in no animals when evaluated in lymph node (data not show). Microscopic
lung scores of the severity of the PRRSV-induced interstitial pneumonia in apical, cardiac,
and dorsal lung lobes were significantly reduced in the FL12-infected group after challenge
when assessed against those of the uninfected control animals (Fig. 4.8).

3.4. Cellular and humoral responses after challenge in uninfected control animals
Following challenge with isolate 16244B, uninfected control animals developed
variable 16244B-specific IFN-γ SC by 14 DPC, with values as low as 25 and as high as
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676 (Fig 4.9A). While at 7 DPC five out of 12 animals were PRRSV seronegative (S/P
ratio < 0.4), all animals had seroconverted by 14 DPC (Fig. 4.9B). Nonetheless,
homologous neutralizing antibody titers were absent by 14 DPC (Fig 4.9C).
To evaluate the cross-reactivity of T cell responses against PRRSV we performed
the IFN-γ ELISpot with PBMC obtained at 14 DPC with nine PRRSV-2 isolates, including
FL12, and one PRRSV-1 strain (Fig. 4.10). We determined that there was a statistical
difference among isolate-specific IFN-γ SC by one-way ANOVA. Simple main effects
analysis showed that 1692-98, 18066-04 and SD01-08 recalled a significantly lower
number of IFN-γ SC than the challenge isolate 16244B. Moreover, the number of SD0108-specific IFN-γ SC was significantly lower than that of FL12, 3805-00, 18565-01, and
MN184C, but not the remaining PRRSV-2 isolates tested.

4. Discussion
Since its emergence, PRRSV has become one of the most important pathogens of
swine. Unlike other relevant viral pathogens of swine—such as classical swine fever and
pseudorabies virus—an effective and broadly-protective vaccine not yet commercially
available (Blome et al., 2017; Freuling et al., 2017). Protection afforded by currentlyavailable commercial PRRSV MLVs is sub-optimal. While reduction in viremia, viral
shedding, and transmission have been observed in MLV-vaccinated animals, outbreaks still
occur in vaccinated herds (Pileri et al., 2015; Wang et al., 2015). Thus, one of the biggest
goals for improving PRRSV vaccines is increasing their cross-protective efficacy.
The starting point for this experiment was the conclusion of our previous crossreactivity study where we demonstrated that T cells of FL12-infected pigs were broadly
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cross-reactive when assessed against a panel of nine progressively divergent PRRSV-2
isolates ranging from 5.02% to 14.48% genome-wide genetic distance. Furthermore, we
proved that the antibody response against PRRSV-2 isolates was also cross-reactive;
however, with few exceptions, we failed to detect any cross-neutralizing antibodies.
Finally, we failed to prove any association between genetic (and antigenic) relatedness of
the recall isolate to FL12 and the strength of the recall T cell response, in line with the
observation of Prieto et al. (2008) that genetic homology between vaccine (in this case
infection) and challenge isolate may not be a predictor of vaccine efficacy.
After a period of convalescence of 77 days, FL12-infected and uninfected control
animals were challenged with the heterologous isolate 16244B. We chose this isolate
because of the medium genome-wide genetic distance to FL12, of 9.66%, and the
variability of 16244B-specific IFN-γ SC at 63 DPI. Charerntantanakul et al. (2006)
demonstrated a correlation between the percentage of homologously-stimulated IFN-γ+ T
cells in PRRSV-vaccinated animals and reduction in both viremia and lung lesion scores
after heterologous challenge. Hence, we hypothesized that in our FL12-infected animals
the number of 16244B-specific IFN-γ SC would be associated with reduced viremia and
microscopic lung lesions.
On the day of the challenge, 77 days after initial infection, most FL12-infected
animals exhibited 200–400 FL12-specific and 100–300 16244B-specific IFN-γ SC.
Surprisingly, at 7 DPC we observed that for half of the animals the number of isolatespecific IFN-γ SC was significantly reduced in comparison to pre-challenge levels.
Although we can not offer a biological explanation for this decline, a similar phenomenon
was observed in PRRSV MLV-vaccinated animals after infectious challenge (Zuckermann
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et al., 2007). It is also possible that this cell-mediated response contraction could be
unrelated to the challenge, as T cell responses in MLV-vaccinated animals have been
shown to fluctuate signficantly during the first three months PI (Meier et al., 2003). In most
animals T cells were up again by 14 DPC, in certain cases up to pre-challenge levels, or
even higher. Contrarily, a small number of animals showed an increase of IFN-γ SC by 7
DPC, followed by a decline by 14 DPC. Of the two animals that exhibited significantly
higher T cell responses during the initial FL12 infection, by 7 DPC animal 301 experienced
a drastic reduction of isolate-specific IFN-γ SC, while animal 314 showed modest to major
increases. While animal 301 died at 7 DPC, animal 314 continued to maintain ~500 isolatespecific IFN-γ SC by 14 DPC. Furthermore, at 14 DPC two other animals, 299 and 304,
also reached ~500 isolate-specific IFN-γ SC for certain PRRSV-2 isolates. Through the 14
days that followed the heterologous challenge we observed great variability of T cell
responses against all PRRSV-2 isolates tested. These data, together with the data from our
cross-reactivity study, leads us to believe that the cell-mediated response against PRRSV
can be erratic, and that host factors must play a significant role in determining its overall
kinetic.
As we previously described in our preceding study, T cell cross-reactivity was
extensive among PRRSV-2 isolates during the 77 days following initial FL12 infection;
however, this did not extend to the PRRSV-1 isolate SD01-08. After heterologous
challenge with a PRRSV-2 isolate this continued to be the case, and the mean isolatespecific IFN-γ SC number for each isolate was, in most cases, increased by 14 DPC.
Interestingly, FL12- nor 16244B-specific IFN-γ SC were the highest by 14 DPC. Instead,
MN184C, a highly pathogenic PRRSV-2 isolate, highly heterologous to both FL12
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(14.32%) and 16244B (13.35%) when genome-wide genetic distances are analyzed seemed
to recall the highest number of isolate-specific IFN-γ SC (Wang et al., 2008). Certain
PRRSV-2 isolates were deemed to have significantly higher IFN-γ SC responses than the
PRRSV-1 strain SD01-08 after challenge, and some significant differences were observed
among PRRSV-2 isolates; nevertheless, we were not able to draw any association between
the isolate genetic distance to the infection strain FL12 or the challenge isolate 16244B,
and the intensity of the T cell response.
All animals were seropositive, as deemed by a commercial PRRSV ELISA, both at
0 and 14 DPC. Only a minor increase in S/P ratios was observed, likely due to our samples
being in the upper portion of the usefull response range of the assay. All FL12-infected
animals had developed neutralizing antibody titers against FL12 previous to challenge,
ranging from 1:4 to 1:128, but only one animal showed a 1:4 neutralizing antibody titer
against 16244B. After heterologous challenge we observed that the neutralizing antibody
titers against FL12 had increased. This could be explained by the natural progression of
the humoral immune response against the original challenge infection or due to a boosting
interaction provided by the heterologous challenge. We observed that nine out of 11
animals had 16244B-neutralizing antibody titers at 14 DPC, which shows that prior
exposure to PRRSV may prime the immune system to generate a much rapid neutralizing
antibody response after challenge. Infectious challenge has also been shown to elicit a rapid
neutralizing antibody response in MLV-vaccinated animals (Trus et al., 2014). Most
interesting were the results indicating that FL12-infected and 16244B-challenged animals
developed neutralizing antibodies to the heterologous isolates 1692-98 and 21599-00.
When considering genome-wide genetic distance, these two isolates are more related to
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FL12, 5.02% genetic distance, than to 16244B, 9.61% genetic distance to 1682-98 and
10.01% to 21599-00. Yet, neutralizing antibody titers of up to 1:32 were observed in five
animals. The same five animals developed neutralizing antibodies against FL12, 16244B,
1692-98, and 21599-00, but no association could be found between the respective titers
(i.e. quantitatively), or between the isolate-specific titers and the number of isolate-specific
IFN-γ SC. Furthermore, one of these animals also developed a neutralizing antibody titer
of 1:16 against isolate 18565-01. Only recently have Robinson et al. (2015) demonstrated
the existence of broadly neutralizing antibody responses against PRRSV in sows that have
endured multiple infections.
Viremia after challenge in the FL12-infected group was short lived and negligible.
Although most of the animals had low, albeit quantifiable, viremia at 3 DPC, only one
animal was viremic at 7 DPC, and all animals were viremia-negative both at 10 and 14
DPC. In sharp contrast, when challenged, our uninfected control group developed viremia
by 3 DPC that peaked at 7 DPC. All uninfected control animals were viremic through the
14 days of duration of the challenge experiment. The reduction of viremia we observed in
the FL12-infected group was significant both when analyzed by repeated measures twoway ANOVA and one-way ANOVA of the AUC. The level of protection afforded by prior
exposure to FL12 was very good, with a seven-fold reduction of the AUC of viremia when
compared to uninfected controls. In an analogous experiment, Vu et al. (2015) observed
that the viremia in FL12-infected pigs challenged 56 DPI with isolate 16244B was reduced
when compared to PBS inoculated animals; however, the viremia in FL12-infected animals
was higher and longer lasting than what we observed in our challenge experiment. We
hypothesize that a longer period of convalescence may explain this observation. In our
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experiment, we did not observe sterilizing immunity in FL12-infected animals. While
Zuckermann et al. (2007) demonstrated that pigs vaccinated with a PRRSV-1 MLV and
challenged with a 7% heterologous strain did not develop viremia, Park et al. (2014) failed
to demonstrate that a PRRSV-2 MLV elicited sterilizing immunity after heterologous
PRRSV challenge. Sterilizing immunity has also been proved in the context of homologous
PRRSV challenge (Lager et al., 1997).
Viral load in PRRSV target tissues—lymph node, tonsil, and lung—was
significantly reduced in FL12-infected animals when compared to uninfected controls.
Furthermore, 16244B-specific RNA was detected in no lymph node samples, and only in
two tonsil samples. Thus, we assume that the viral RNA detected in the remaining tissue
samples belongs to the ongoing chronic and persistent replication of FL12 from the initial
infection. Although our viral RNA quantification results are in line with those presented
by Vu et al. (2015), the levels of 16244B-specific viral RNA in lymph node and tonsil
appear significantly reduced in our FL12-infected animals. Again, we hypothesize that a
longer interval between infection and challenge could account for this difference. MLV
vaccination was also shown to produce a significant reduction in viral RNA in tonsil, and
a total elimination of viral RNA from lung, the latter in contrast to our observations
(Zuckermann et al., 2007). Microscopic lung scores were significantly reduced in FL12infected animals when compared to uninfected control animals. Regardless, many of these
animals still developed diffuse to moderate diffuse interstitial pneumonia after challenge
in all examined lung lobes.
The uninfected control animals developed a solid viremia after challenge—which
began to decline by 10 DPC—with severe diffuse interstitial pneumonia accompanied in
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some cases with collapse of the alveoli. Unlike our four-week old pigs in the crossreactivity study, these pigs developed a rapid 16244B-specific IFN-γ SC response by 14
DPC. Moreover, in our experiment 75% of 16244B-challenged animals developed high
heterologous IFN-γ SC responses (> 115 IFN-γ SC/106 PBMC) by 14 DPC, while in a
previous experiment only 12% of MLV-vaccinated piglets did so by 28 DPI (Xiao et al.,
2004). We presume that the differences observed between these three studies are associated
with the age of the animals at the time of infection or challenge, and the ability of the strain
or isolate to stimulate the T cell response. This we had already suggested in our previous
cross-reactivity study, as natural infection seems to elicit higher IFN-γ SC responses than
MLV vaccination. Although it was previously shown that natural infection may elicit more
potent cell-mediated immune responses, no difference was observed between the T cell
responses in piglets and finisher pigs (Klinge et al., 2009).
The humoral immune responses in the uninfected control group were characteristic
for PRRSV infection. Many animals were seropositive by ELISA by 7 DPC, and all had
seroconverted by 14 DPC. Nonetheless, and in contrast with the sharp induction of IFN-γ
SC, no homologous neutralizing antibody titers were detected. It is widely accepted that
neutralizing antibodies against PRRSV only appear 28 DPI or later, while cell-mediated
immune responses can be detected as early as 14 DPI (Lopez and Osorio, 2004; Meier et
al., 2003; Xiao et al., 2004). Analogous to what we describe in our cross-reactivity study
(before and after challenge), the IFN-γ SC response in the uninfected control animals
challenged with isolate 16244B was broadly cross-reactive. By 14 DPC the isolate-specific
number of IFN-γ SC was not significantly different amongst most PRRSV-2 strains and
isolates tested, and was significantly higher for many PRRSV-2 isolates when compared
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to the PRRSV-1 strain SD01-08. This further cements the notion that T cells are broadly
cross-reactive between PRRSV-2 isolates.
Our results demonstrate that prior infection with PRRSV affords solid protection to
heterologous challenge. Unlike homologous challenge, or—potentially—certain MLVs,
prior infection did not provide sterilizing levels of immunity; however, prior infection does
seem to reduce the magnitude and duration of viremia, the viral burden in PRRSV target
tissues, and the extent and severity of interstitial pneumonia. The data presented is of
relevance, due to the wide use of live virus infection to inoculate naïve replacement gilts
in herd closure and stabilization protocols. Live virus inoculation is preferred in many cases
because it affords better protection against viruses circulating in the herd (i.e. homologous)
(Dee, 2003; FitzSimmons and Daniels, 2003). Here we demonstrate that live virus
inoculation also elicits a cross-protective immune response that may be as effective, or
even better, than that afforded by MLVs. Herd closure and stabilization with live virus
inoculation is an effective and established method to eradicate PRRSV from a herd or farm;
yet, it should be noted that live virus inoculation is not without risks, and that risks and
benefits should be weighed before pursuing this control and eradication strategy.
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Figure 4.1. Experimental design of cross-protection study. Chronology of animal
experiment. After an acclimatization period of one week, animals were infected with
PRRSV-2 strain FL12 (n=12) at 0 DPI (q) or left uninfected (n=12). All animals were
challenged with PRRSV-2 isolate 16244B at 77 DPI (s) and humanely euthanized and
necropsied at 91 DPI (p).
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Figure 4.2. FL12- and 16244B-specific IFN-γ SC responses in FL12-infected animals after
challenge. FL12-specific (A) and 16244B-specific (B) IFN-γ SC were detected in PBMC
by ELISpot assay at the indicated times.
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Figure 4.3. Heterologous strain- and isolate-specific IFN-γ SC responses in FL12-infected
animals after challenge. Isolate-specific IFN-γ SC were detected in PBMC by ELISpot
assay at the indicated times (A–I).
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Figure 4.4. IFN-γ SC cross-reactivity in FL12-infected animals after challenge. (A) The
mean and standard error IFN-γ SC number was calculated for each PRRSV isolate used as
recall antigen. (B) The IFN-γ SC AUC mean and standard error for each isolate was
calculated.
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Figure 4.5. Humoral immune responses in FL12-infected animals after challenge. (A)
Antibody responses against PRRSV were evaluated by ELISA, an S/P ratio ≥ 0.4 was
considered positive. (B–F) Isolate-specific neutralizing antibody titers were determined by
SVN and results are expressed as the log2 of the reciprocal of the largest dilution of serum
that inhibited the development of virus in cell culture.
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Figure 4.6. Viremia after challenge. (A) Viremia was determined by quantitative real time
RT-PCR at the indicated time points. (B) The viremia AUC was calculated using the
trapezoidal rule.
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Figure 4.7. Viral RNA quantification in target tissues after challenge. Viral RNA copies
per µg of RNA were determined by quantitative real time RT-PCR at 91 DPI in lymph
node (A), tonsil (B), and lung (C).
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Figure 4.8. Microscopic lung scores after challenge. Sections of the apical (A), cardiac (B),
and dorsal (C) lung lobes were blindly examined by a pathologist and given an estimated
score of the severity of the interstitial pneumonia.
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Figure 4.9. Homologous cellular and humoral immune responses in uninfected animals
after challenge. (A) 16244B-specific IFN-γ SC were detected in PBMC by ELISpot assay
at the indicated times. (B) Antibody responses against PRRSV were evaluated by ELISA,
an S/P ratio ≥ 0.4 was considered positive. (C) Neutralizing antibody titers against 16244B
were determined by SVN and results are expressed as the log2 of the reciprocal of the
largest dilution of serum that inhibited the development of virus in cell culture.
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Figure 4.10. Cross-reactivity of IFN-γ SC responses in uninfected animals after challenge.
The mean and standard error IFN-γ SC number at 91 DPI was calculated for each PRRSV
isolate used as recall antigen.
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1. Abstract
The two species of PRRSV—previously considered genotypes of the same taxon—
have only a ~60% genetic homology. The protection afforded by MLVs of one species
against the other species is usually worse than the already incomplete protection observed
within each species. Nevertheless, it has recently been shown that certain PRRSV MLVs
may afford better cross-protection against opposite species challenge. In this context,
weakly cross-reactive IFN-γ SC responses were observed. In our previous experiments we
described cross-species reactive IFN-γ SC in equivalent magnitudes. Because the structural
proteins of PRRSV have been shown to contain several immunodominant, and sometimes
conserved, T cell epitopes, we evaluated the levels of T cell cross-reactivity in SD01-08infected animals, a PRRSV-1 strain, against the structural proteins of FL12, a PRRSV-2
strain. When compared to mock-infected control animals, the cell-mediated immune
response in SD01-08-infected animals was not significantly increased against the structural
proteins of FL12. Moreover, prior infection with PRRSV-1 did not seem to prime the cellmediated immune response against the PRRSV-2 structural proteins, as the magnitude of
IFN-γ SC numbers between the mock-infected control group and the SD01-08-infected
group was not significantly different after challenge with FL12.

121
2. Introduction
The first reports of PRRSV can be tracked to the non-peer reviewed literature in
the late 1980’s (Keffaber, 1989). Since then, PRRSV has spread to most swine-producing
countries, and in the United States alone the disease is estimated to generate upwards of
$664 million in economic losses. PRRSV causes reproductive failure in pregnant sows and
respiratory disease in young pigs, belongs to the family Arteriviridae, and is an enveloped,
positive-sense, single-stranded RNA virus (Rossow, 1998; Snijder et al., 2013).
PRRSV was previously divided into two genotypes, type 1 or European and type 2
or North American, but the current taxonomy classifies each former genotype into a new
species, PRRSV-1 and PRRSV-2, respectively (Adams et al., 2016; Adams et al., 2017).
Although the extraordinary genetic and antigenic variability between these viruses was
demonstrated decades ago, recent analysis of coding-complete genomes and ORF1b
phylogeny precipitated the separation into two distinct species (Kuhn et al., 2016;
Murtaugh et al., 1995; Nelsen et al., 1999; Nelson et al., 1993). About 40% genetic
difference exists between PRRSV-1 and PRRSV-2 (Murtaugh et al., 2010).
Through mechanisms that include the use of PRFs and sg mRNAs, the otherwise
short PRRSV genome, at 14.9–15.5 kb, encodes 11 ORFs which, once processed, yield up
to 24 distinct protein products (Kappes and Faaberg, 2015). The PRRSV structural proteins
are encoded by ORFs contained within a set of six sg mRNAs that are generated via
negative-strand intermediates from the 3’-proximal portion of the genome (Meng et al.,
1996). GP2-4 associate to form a heterotrimer on the surface of the virion and mediate
interaction with the PRRSV major cellular receptor CD163 (Das et al., 2010). GP5 and M
form a disulfide-linked heterodimer on the PRRSV envelope that is essential for virus
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structure and assembly, with a questioned role in mediating attachment to the host cells
(Van Breedam et al., 2010; Wissink et al., 2005). The N protein forms the nucleocapsid
core of the virion with a potential responsibility in viral assembly and budding (Dokland,
2010; Spilman et al., 2009). The antigenic homology between the structural ORFs of
PRRSV-1 and PRRSV-2 is variable, with amino acid sequence identities ranging from 54%
for GP5 to 91% for the M protein (Meng et al., 1995a; Meng et al., 1995b; Murtaugh et al.,
1995).
Among the multiple proteins of PRRSV, structural protein peptides from GP2,
GP3, GP4, GP5, M, and N were shown to be recognized by T cells of PRRSV-infected
animals (Mokhtar et al., 2014). Immunodominant T cell epitopes have been mapped to
most structural proteins—GP4, GP5, M, and N—and appear to be moderately conserved
within each species, and to a lesser extent across PRRSV-1 and PRRSV-2 (Diaz et al.,
2009; Vashisht et al., 2008; Wang et al., 2011).
Cross-protection between PRRSV-1 and PRRSV-2 was assumed to be very limited,
as PRRSV-2 MLVs have shown weak efficacy after PRRSV-1 infectious challenge
(Labarque, 2003; Labarque et al., 2000; van Woensel et al., 1998). On the contrary, Park
et al. (2015) demonstrated that a PRRSV-2 MLV afforded significant cross-protection
against PRRSV-1 challenge, as measured by reduction in viremia, viral shedding, and
microscopic lung lesions. Equivalent results were also observed with a PRRSV-1 MLV
(Kim et al., 2015). How cross- protection between PRRSV species occurs is not yet fully
understood. Pigs infected or MLV-vaccinated with either PRRSV-1 or PRRSV-2 strains
were shown to recall small numbers of IFN-γ SC against the opposite species, and crossneutralizing antibodies were absent (Burgara-Estrella et al., 2013; Choi et al., 2016; Kim
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et al., 2015). In our cross-reactivity and cross-protection experiments we observed
extremely weak IFN-γ SC recall responses against PRRSV-1 strain SD01-08 in PRRSV2-infected animals. Hence, to gain a better understanding of how cross-species protection
may arise, and to further examine the immunodominance of structural proteins, we planned
to evaluate the cross-reactivity of IFN-γ SC responses in SD01-08-infected animals against
the structural proteins of FL12.
In this experiment, we infected a group of six four-week old pigs with the North
American PRRSV-1 strain SD01-08 and six animals were mock-infected with PBS (Fig.
5.1). At 56 DPI, all animals were challenged with PRRSV-2 strain FL12 and humanely
euthanized 14 days later. Cell-mediated immune responses were assessed at 0, 56 and 70
DPI against peptide pools representing the structural proteins of FL12: GP2, GP3, GP4,
GP5, M, and N. This allowed us to evaluate the T cell cross-reactivity between PRRSV-1
and PRRSV-2 at the structural protein level.

3. Results
3.1. Nucleotide and amino acid pairwise distance between the structural proteins of
SD01-08 and FL12
Genome-wide coding nucleotide pairwise distance between SD01-08 and FL12
was calculated at 36.72% and ORF-level nucleotide and amino acid sequences were
aligned using MUSCLE (Edgar, 2004). Nucleotide and amino acid calculated pairwise
distances by ORF are presented in Table 5.1.
The highest calculated nucleotide pairwise distance between the structural ORFs of
SD01-08 and FL12 belongs to ORF5, which codes for GP5, at 34.80%. ORF7, that codes
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for the N protein, has the lowest calculated nucleotide pairwise distance between these two
strains at 29.44%. Amino acid-wise, ORF5 continues to be the most distant between these
two strains, with a calculated amino acid pairwise distance of 42.54%, while the M protein,
encoded by ORF6, is the most conserved, at 21.39%.

3.2. Cell-mediated responses against the structural proteins of FL12 in SD01-08-infected
animals
SD01-08-infected animals were allowed 56 days to reach convalescence before
determining the level of IFN-γ SC recalled by structural peptides of the heterologous
PRRSV-2 strain FL12. The number of IFN-γ SC recalled by GP2, GP3, GP4, GP5, M, and
N peptide pools was not significantly different between the SD01-08-infected and mockinfected groups as determined by an unpaired t-test (Fig. 5.2). The IFN-γ SC recall
responses of individual animals against these peptides was negligible, in most cases under
10 IFN-γ SC/106 PBMC. When PBMC were re-stimulated with an M protein peptide pool
two animals exhibited higher IFN-γ SC recall responses, at 31 and 54 IFN-γ SC/106 PBMC.
A moderately higher IFN-γ SC recall response was also observed in one of these animals
against an N protein peptide pool, at 19 IFN-γ SC/106 PBMC.

3.3. Cell-mediated responses against the structural proteins of FL12 in SD01-08-infected
animals after challenge
At 56 DPI, all animals were challenged with the PRRSV-2 strain FL12 and the
number of IFN-γ SC recalled by peptide pools of the structural proteins of FL12 were
determined 14 DPC (Fig. 5.3). One of the animals in the mock-infected PBS group
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unexpectedly died due to causes not associated with this study. Unpaired t-test analysis
failed to demonstrate significance between the SD01-08- and mock-infected groups for all
six structural ORFs evaluated. IFN-γ SC recall responses were marginally diminished in
the SD01-08-infected group against the minor glycoproteins (GP2-4) and the N protein,
but slightly increased against the major glycoprotein, GP5, and the M protein, when
compared to the mock-infected group.

4. Discussion
The established paradigm that PRRSV was a sole, albeit extremely variable, species
within the genus Arterivirus was recently replaced by the introduction of new molecular
phylogeny analysis tools (Kuhn et al., 2016). While the former European or type 1 strains
and isolates remained in the former PRRSV taxon, now renamed PRRSV-1, the North
American or type 2 strains and isolates were re-classified into a newly-created PRRSV-2
taxon. These taxa join the prototype species LaDV in the newly-formed genus Porartevirus
of the family Arteriviridae (Adams et al., 2016; Adams et al., 2017).
The recent demonstration that vaccination with either a PRRSV-1 or a PRRSV-2
MLV can reduce both viremia and microscopic lesions after opposite species challenge
disputed the notion that PRRSV MLVs did not afford significant cross-species or crossgenotype protection (Kim et al., 2015; Labarque et al., 2000; Park et al., 2015; van Woensel
et al., 1998). Furthermore, it was shown that vaccination or infection with one species of
PRRSV elicited a weak cross-species reactive IFN-γ SC response (Burgara-Estrella et al.,
2013; Choi et al., 2016; Kim et al., 2015). Our prior results clearly demonstrated that IFNγ SC responses were broadly cross-reactive between PRRSV-2 isolates, but when PBMC
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from FL12-infected animals were re-stimulated with a PRRSV-1 strain the number of IFNγ SC recalled was, although present, significantly lower.
In this experiment we further assessed the cross-reactivity between PRRSV-1 and
PRRSV-2 at the structural ORF level. Although immunodominant T cell epitopes have
been mapped to both structural and non-structural proteins, the former seem to consistently
elicit higher T cell responses in a broader number of animals (Diaz et al., 2009; Mokhtar
et al., 2014; Parida et al., 2012). In the current study PBMC obtained from pigs infected
with the North American PRRSV-1 strain SD01-08 failed to recall a significant number of
IFN-γ SC against peptide pools representing the structural proteins of the PRRSV-2 strain
FL12, when compared to mock-infected animals. Our results show that, with few
exceptions, the six animals in the SD01-08-infected group only presented meager T cell
responses against GP2-5, M, and N peptide pools. A notable exception occurred when
PBMC were re-stimulated with peptide pools corresponding to the M protein, in which
case we observed that two animals had improved T cell responses. We hypothesize that the
conserved nature of the M protein, at 21.39% calculated amino acid pairwise distance,
could be responsible for this observation. The distribution of SLA molecules in an outbred
pig population cannot be underestimated, as this observation could only be explained if
these animals had distinct haplotypes, and thus, different abilities to present and recognize
peptides in the context of their respective SLA molecules.
We were also interested in evaluating if prior exposure to a PRRSV species had a
priming effect after challenge with the opposite species. To that effect, we challenged all
animals with the PRRSV-2 strain FL12, and 14 days later evaluated their cell-mediated
immune responses. Once again, our results showed no statistically significant difference
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between the group of animals that had been previously infected with SD01-08 and that
mock-infected. This was true for all the structural proteins tested. Hence, prior exposure to
PRRSV-1 does not seem to prime the cell-mediated immune response against challenge
with PRRSV-2.
The experimental data here presented regarding cross-species reactivity between
the North American PRRSV-1 strain SD01-08 and PRRSV-2 strain FL12 conforms with
those data previously presented for both our cross-reactivity and cross-protection studies.
Although we failed to prove any statistical difference between PRRSV-1-infected and
mock-infected animals, we did observe that individual animals may have IFN-γ SC recall
responses in the context of PRRSV-2 peptides. In a smaller magnitude, our findings are in
line with the recent reports of cross-protection and weak cross-reactivity between PRRSV1 and PRRSV-2 (Burgara-Estrella et al., 2013; Choi et al., 2016; Kim et al., 2015; Park et
al., 2015).
Certain bacterial and viral vaccines have been shown to afford cross-species
protection. A Brucella suis MLV was shown to protect against B. suis and cross-protect
against B. abortus and B. mellitenesis challenge in mice; however, these are considered
closely related strains (Halling et al., 2005; Zhu et al., 2016). Although vaccination with a
bovine herpesvirus-1 MLV was proven to protect against heterologous bubaline
herpesvirus-1 challenge, these two viruses have an almost identical glycoprotein B, with
96.6% nucleotide homology, which is a major target of neutralizing antibodies (Alves
Dummer et al., 2014; Montagnaro et al., 2014). Approximately 35% genetic difference
exists between measles virus and canine distemper virus, both members of the genus
Morbillivirus, family Paramyxoviridae. Cross-species protection has been observed in

128
dogs and non-human primates vaccinated with measles virus and challenged with canine
distemper virus. Cross-neutralizing cellular immune responses were assumed to mediate
the observed cross-protection, and while cross-neutralizing antibodies were not detected
prior to challenge, the presence cross-reactive virus neutralizing epitopes was suggested
(de Vries et al., 2014). T cell-mediated immune responses—CD4+ IFN-γ+ or IFN-γ+/TNFα+ cells—triggered by both homologous or heterologous re-stimulation has been observed
for both Chlamydia suis and C. trachomatis infection (Kaser et al., 2017). Again, C. suis
and C. trachomatis are closely related bacterial strains (Hadfield et al., 2017).
Although our results do not reveal a significant cell-mediated immune response
against the PRRSV-2 structural proteins in PRRSV-1-infected animals, they still
demonstrate that certain individuals may be able to weakly recognize cross-reactive
epitopes between both species. Other authors have confirmed the existence of crossprotective immunity between both PRRSV species. In the absence of neutralizing
antibodies—the best characterized correlate of protection for PRRSV—the question of
whether these limited cross-reactive T cell responses could be responsible for the observed
reduced levels of viremia, viral shedding, and microscopic lung lesions remains
unanswered. The extraordinary genetic variability of PRRSV, coupled with the immense
variability of SLA haplotypes, constitute a great obstacle for identifying immunodominant
T cell epitopes. Nonetheless, evidence for non-sterilizing cross-protection in the absence
of neutralizing antibodies, both within and between PRRSV species, continues to push
forward the concept that T cells are a major component of the cross-reactive immune
response against PRRSV.
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Table 5.1. Calculated nucleotide and amino acid pairwise distance (%) between the
ORFs of SD01-08 and FL12.
ORF (Protein)

Nucleotide

Amino Acid

ORF1a (nsp1-8)

37.62

50.00

ORF1b (nsp9-12)

34.57

30.89

ORF2a (GP2)

32.84

34.17

ORF3 (GP3)

32.23

39.04

ORF4 (GP4)

33.40

29.78

ORF5 (GP5)

34.80

41.54

ORF6 (M)

31.03

21.39

ORF7 (N)

29.44

34.17
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Figure 5.1. Experimental design of cross-species reactivity study. Chronology of animal
experiment. After an acclimatization period of one week, animals were infected with
PRRSV-1 strain SD01-08 (n=6) at 0 DPI (q) or mock-infected with PBS (n=6). All
animals were challenged with PRRSV-2 strain FL12 at 56 DPI (s) and humanely
euthanized at 70 DPI.
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Figure 5.2. IFN-γ SC recall responses in SD01-08-infected animals against FL12 structural
protein peptide pools. PBMC obtained at 56 DPI from SD01-08- and mock-infected
animals were re-stimulated with peptide pools representing the structural proteins of FL12
and IFN-γ SC determined by ELISpot assay. Data were analyzed by unpaired t-test, and pvalues are presented.
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Figure 5.3. IFN-γ SC recall responses in SD01-08-infected and challenged animals against
FL12 structural protein peptide pools. PBMC obtained at 70 DPI (14 DPC) from SD01-08and mock-infected animals were re-stimulated with peptide pools representing the
structural proteins of FL12 and IFN-γ SC determined by ELISpot assay. Data were
analyzed by unpaired t-test, and p-values are presented.
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GENERAL DISCUSSION AND CONCLUSIONS

The economic burden associated with PRRSV infection is on the rise, and both
PRRSV-1 and PRRSV-2 are present in Asia, North America, and Europe, where most of
the world’s swine production is concentrated. The genetic and antigenic variability of the
virus and its outstanding capacity to evolve are a major hurdle for controlling and
eliminating PRRSV. Nonetheless, several strategies have been demonstrated to be effective
against it. While gilt acclimatization is commonly used to reduce the incidence of PRRSVassociated disease in naïve animals, herd stabilization and closure are the most widely used
method for eliminating PRRSV from a farm (Corzo et al., 2010; Linhares et al., 2014;
Torremorell et al., 2002). The effectiveness of the hosts’ immune response against the virus
can be illustrated by the success of herd stabilization and closure protocols, where PRRSV
negative status can be achieved by limiting the introduction of susceptible animals while
allowing those already infected to eliminate the virus. The success of these protocols is
reliant on long periods of time where animals are not introduced into the herd (Loving et
al., 2015). The absence of DIVA vaccines against PRRSV, the suboptimal protection
afforded by MLV vaccination—outbreaks have been documented in well-vaccinated
herds—and the extended periods of time required by current eradication strategies may
make unrealistic a long-term and large-scale eradication of PRRSV (Vu et al., 2017; Wang
et al., 2015). Thus, there is a pressing need to improve PRRSV vaccines, fundamentally in
regard to their cross-protective efficacy which, in turn, would make PRRSV eradication
much more feasible.
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Immunity against PRRSV is complete and sterilizing in the presence of appropriate
titers of neutralizing antibodies against homologous virus challenge (Lager et al., 1997;
Osorio et al., 2002). Nonetheless, commercially available MLVs are poor inducers of
neutralizing antibodies, and cross-neutralizing antibodies against heterologous isolates are
rare to occur (Kim et al., 2007; Lopez and Osorio, 2004). Recently, broadly neutralizing
antibodies have been shown to occur in sows with multiple exposures to PRRSV (Robinson
et al., 2015). Partial protection against heterologous challenge is afforded by MLV
vaccination, and it is assumed to be mediated by T cells (Zuckermann et al., 2007). The
extent to which T cells may cross-react with heterologous PRRSV isolates is unknown.
Thus, if protection can be afforded by cell-mediated responses, there is a necessity to
characterize how these behave against the extensive genetic and antigenic array of PRRSV.
Chapter III described the extensive variability observed in cell-mediated immune responses
in PRRSV-infected animals against both homologous and heterologous isolates. When
individual animal T cell responses against PRRSV were evaluated over a period of 11
weeks, a significant variation was observed. While certain animals had robust T cell
responses within two to four weeks after infection, others required over eight weeks to
attain modest levels of PRRSV-specific IFN-γ SC. Most importantly, cell-mediated
responses in PRRSV-2-infected animals were shown to be broadly cross-reactive against
other PRRSV-2 isolates, but not against a PRRSV-1 strain, and that increased genetic
heterology between PRRSV-2 isolates was not associated with reduced T cell responses.
Although cell- and antibody-mediated responses were cross-reactive, no cross-reactive
neutralizing antibodies were detected, regardless of genetic distance to the infection isolate.
Finally, a moderate correlation between homologous T cell and neutralizing antibody
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responses was described. Taken together, these results demonstrate that T cell responses
against PRRSV-2 are cross-reactive to other PRRSV-2 isolates regardless of genetic
distance, and may be mediate partial protection against heterologous challenge.
Because Charerntantanakul et al. (2006) demonstrated that a higher presence of
PRRSV-specific IFN-γ+ SC in MLV vaccinated animals was associated with reduction in
viremia and microscopic lung lesions after challenge, the relative contribution of IFN-γ SC
in FL12-infected animals against heterologous challenge was evaluated. To assess the
extent of protection afforded by prior exposure to PRRSV, previously uninfected control
animals were concurrently challenged. Immediately before challenge, the homologous
(against strain FL12) T cell responses were higher than heterologous (against isolate
16244B) ones, with the latter ranging between 100 and 300 IFN-γ SC/106 PBMC. During
the 14 days following challenge an array of divergent patterns were observed. While some
animals experienced a boost in both homologous and heterologous T cell responses at 7
DPC, others experienced a decline. At 14 DPC this pattern repeated, with PRRSV-specific
T cells in certain animals bouncing back, and in others going down. Overall, the mean T
cell response for both homologous and heterologous virus was slightly boosted after
challenge. As in the previous chapter, extensive cross-reactivity between PRRSV-2 isolates
was observed. Furthermore, FL12-infected animals developed 16244B neutralizing
antibodies within 14 days after challenge, and more importantly, cross-neutralizing
antibodies against other heterologous isolates. Although the challenge data showed strong
reduction of viremia, the viral load in lymph node and microscopic lung lesion were
modestly, albeit significantly, reduced. 16244B-specific RNA in lymph node and tonsil
was not detected, thus, the viral RNA quantified in those tissues corresponds to the ongoing
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chronic infection of the primary inoculation with FL12. In the uninfected animals, a
relatively homogeneous rapid development of T cell responses against homologous (in this
case 16244B) and heterologous PRRSV-2 isolates was observed as early as 14 DPC, in
sharp contrast to what occurred in our initial cross-reactivity study. This supports the
hypothesis that the development T cell responses may be influenced by the age of the
animal. Overall, these data demonstrate that previous infection with PRRSV affords
protection against heterologous challenge, that manifests as solid reduction of viremia post
challenge, as well as significant reduction in tissue viral load and microscopic lung lesions.
Furthermore, it continues to advance the notion that T cells mediate heterologous
protection against PRRSV. Finally, it proves that broadly neutralizing antibody responses
can be achieved against PRRSV.
Chapter V describes the efforts to better characterize the cross-reactivity of T cell
responses between PRRSV-1 and PRRSV-2 at the structural protein level. Cell-mediated
responses against the structural proteins of PRRSV are strong, and several T cell epitopes
have been mapped to them, some of which are conserved (Bautista et al., 1999; Diaz et al.,
2009; Vashisht et al., 2008; Wang et al., 2011). Re-stimulating PBMC of SD01-08-infected
animals, a PRRSV-1 strain, with peptide pools representing the structural proteins of FL12,
a PRRSV-2 strain, did not elicit a significant T cell responses when compared to those of
PBMC from mock-infected animals. Nevertheless, isolated episodes in which certain
animals had apparent cross-reactive T cells against the M and N proteins were detected,
though in a very limited capacity. Moreover, prior exposure to PRRSV-1 did not seem to
prime the T cell response against PRRSV-2 challenge, as SD01-08-infected animals
challenged with FL12 showed similar numbers of IFN-γ SC against the structural proteins
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of FL12 than mock-infected and challenged animals. Therefore, and in unison with the
results presented in the two previous chapters, there doesn’t seem to be a cross-reactive
cell-mediated immune response between the structural proteins of PRRSV-1 and PRRSV2.
Overall, the results presented in this dissertation further our understanding of
humoral, but fundamentally cell-mediated immunity against PRRSV, and continues to
advance our knowledge of swine immunology. Furthermore, these results can contribute
to the ongoing efforts of developing broadly-protective vaccines against PRRSV that will
in turn advance the eradication efforts against the virus.
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APPENDICES

A.1.

Phosphate buffered saline (PBS)
NaCl

140 mM

KCl

2.7 mM

Na2HPO4

10 mM

KHPO4

1.8 mM
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